JPWO2021173896A5

JPWO2021173896A5 -

Info

Publication number: JPWO2021173896A5
Application number: JP2022551584A
Authority: JP
Publication date: 2024-03-06

Description

当業者は、広い発明概念から逸脱することなく、上で説明される実施形態に変更を行うことができることを理解するであろう。したがって、本発明は、開示された特定の実施形態に制限されず、本説明によって定義されるように本発明の趣旨及び範囲内の修正を包含することを意図するものと理解される。

以下の態様が包含され得る。
［１］Ｔ細胞受容体γ可変９（ＴＲＧＶ９）に結合する抗体であって、
（１）（ｉ）それぞれ、配列番号１０４のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号１０５のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、
（２）（ｉ）それぞれ、配列番号１１３のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号１１４のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、
（３）（ｉ）それぞれ、配列番号１２３のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号１２４のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、又は
（４）（ｉ）それぞれ、配列番号１３３のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号１３４のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、を含む、抗体。
［２］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、Ｋａｂａｔ付番システムに従う、上記［１］に記載の抗体。
［３］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、Ｃｈｏｔｈｉａ付番システムに従う、上記［１］に記載の抗体。
［４］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、ＡｂＭ付番システムに従う、上記［１］に記載の抗体。
［５］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、Ｃｏｎｔａｃｔ付番システムに従う、上記［１］に記載の抗体。
［６］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、ＩＭＧＴ付番システムに従う、上記［１］に記載の抗体。
［７］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、例示的な付番システムに従う、上記［１］に記載の抗体。
［８］前記抗体が、ヒト化抗体である、上記［１］～［７］のいずれか一項に記載の抗体。
［９］前記抗体が、ＩｇＧ抗体である、上記［１］～［８］のいずれか一項に記載の抗体。
［１０］前記ＩｇＧ抗体が、ＩｇＧ１、ＩｇＧ２、ＩｇＧ３、又はＩｇＧ４抗体である、上記［９］に記載の抗体。
［１１］前記抗体が、κ軽鎖を含む、上記［１］～［１０］のいずれか一項に記載の抗体。
［１２］前記抗体が、λ軽鎖を含む、上記［１］～［１０］のいずれか一項に記載の抗体。
［１３］前記抗体が、モノクローナル抗体である、上記［１］～［１２］のいずれか一項に記載の抗体。
［１４］前記抗体が、ＴＲＧＶ９抗原に結合する、上記［１］～［１３］のいずれか一項に記載の抗体。
［１５］抗体が、ＴＲＧＶ９エピトープに結合する、上記［１］～［１３］のいずれか一項に記載の抗体。
［１６］前記抗体が、ＴＲＧＶ９に特異的に結合する、上記［１］～［１５］のいずれか一項に記載の抗体。
［１７］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３が、前記ＴＲＧＶ９の抗原に対する結合部位を形成する、上記［１］～［１６］のいずれか一項に記載の抗体。
［１８］前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３が、前記ＴＲＧＶ９のエピトープに対する結合部位を形成する、上記［１］～［１６］のいずれか一項に記載の抗体。
［１９］前記ＴＲＧＶ９が、Ｔ細胞の表面上に存在する、上記［１］～［１８］のいずれか一項に記載の抗体。
［２０］前記抗体が、多価である、上記［１］～［１９］のいずれか一項に記載の抗体。
［２１］前記抗体が、少なくとも３つの抗原に結合することができる、上記［２０］に記載の抗体。
［２２］前記抗体が、少なくとも４つの抗原に結合することができる、上記［２０］に記載の抗体。
［２３］前記抗体が、少なくとも５つの抗原に結合することができる、上記［２０］に記載の抗体。
［２４］前記抗体が、多重特異性抗体である、上記［１］～［２３］のいずれか一項に記載の抗体。
［２５］多重特異性ＴＲＧＶ９抗体であって、
（ａ）ＴＲＧＶ９に結合する第１の結合ドメインと、ここで、前記第１の結合ドメインは、上記［１］～［２３］のいずれか一項に記載のＴＲＧＶ９抗体を含む、
（ｂ）ＴＲＧＶ９ではない第２の標的に結合する第２の結合ドメインと、を含む、多重特異性ＴＲＧＶ９抗体。
［２６］前記抗体が二重特異性抗体である、上記［２５］に記載の多重特異性ＴＲＧＶ９抗体。
［２７］前記抗体が三重特異性抗体である、上記［２５］に記載の多重特異性ＴＲＧＶ９抗体。
［２８］前記抗体が四重特異性抗体である、上記［２５］に記載の多重特異性ＴＲＧＶ９抗体。
［２９］前記第２の結合ドメインが、前記第２の標的の抗原に結合する、上記［２５］～［２８］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［３０］第２の結合ドメインが、前記第２の標的のエピトープに結合する、上記［２５］～［２８］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［３１］前記第２の結合ドメインが、前記第２の標的に特異的に結合する、上記［２５］～［３０］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［３２］前記第２の結合ドメインの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３が、前記第２の標的の抗原の結合部位を形成する、上記［２５］～［３１］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［３３］前記第２の結合ドメインの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３が、前記第２の標的のエピトープの結合部位を形成する、上記［２５］～［３１］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［３４］前記第２の標的が、標的細胞の表面上に存在する、上記［２５］～［３３］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［３５］前記第２の標的に結合する前記第２の結合ドメインが、多価である、上記［２５］～［３４］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［３６］前記第２の結合ドメインが、少なくとも３つの抗原に結合することができる、上記［３５］に記載の多重特異性ＴＲＧＶ９抗体。
［３７］前記第２の結合ドメインが、少なくとも４つの抗原に結合することができる、上記［３５］に記載の多重特異性ＴＲＧＶ９抗体。
［３８］前記第２の結合ドメインが、少なくとも５つの抗原に結合することができる、上記［３５］に記載の多重特異性ＴＲＧＶ９抗体。
［３９］前記第２の標的が、ＣＤ１２３である、上記［２５］～［３８］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［４０］ＣＤ１２３に結合する第２の結合アームが、（ｉ）それぞれ、配列番号１５のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨと、（ｉｉ）それぞれ、配列番号１６のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬと、を含む、上記［３９］に記載の多重特異性ＴＲＧＶ９抗体。
［４１］多重特異性ＴＲＧＶ９抗体であって、
（ａ）ＴＲＧＶ９に結合する第１の結合ドメインと、ここで、前記第１の結合ドメインは、
（１）（ｉ）それぞれ、配列番号７のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号８のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、
（２）（ｉ）それぞれ、配列番号３４のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３、並びに（ｉｉ）それぞれ、配列番号８のアミノ酸配列を有する軽鎖可変領域（ＶＬ）のＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、
（３）（ｉ）それぞれ、配列番号３５のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号８のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、
（４）（ｉ）それぞれ、配列番号３６のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号８のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、
（５）（ｉ）それぞれ、配列番号６５のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号６６のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、
（６）（ｉ）それぞれ、配列番号６７のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号６８のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、又は
（７）（ｉ）それぞれ、配列番号９５のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨ、並びに（ｉｉ）それぞれ、配列番号９６のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬ、を含む、
（ｂ）ＣＤ３３、ＴＲＢＣ１、ＢＣＭＡ、又はＰＳＭＡである第２の標的に結合する第２の結合ドメインと、を含む、多重特異性ＴＲＧＶ９抗体。
［４２］前記第２の標的が、ＣＤ３３である、上記［２５］～［３５］又は［４１］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［４３］ＣＤ３３に結合する前記第２の結合アームが、（ｉ）それぞれ、配列番号４３のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨと、（ｉｉ）それぞれ、配列番号４４のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬと、を含む、上記［４２］に記載の多重特異性ＴＲＧＶ９抗体。
［４４］前記第２の標的が、ＴＲＢＣ１である、上記［２５］～［３８］又は［４１］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［４５］ＴＲＢＣ１に結合する前記第２の結合アームが、（ｉ）それぞれ、配列番号５５のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨと、（ｉｉ）それぞれ、配列番号５６のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬと、を含む、上記［４４］に記載の多重特異性ＴＲＧＶ９抗体。
［４６］前記第２の標的が、ＢＣＭＡである、上記［２５］～［３８］又は［４１］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［４７］ＢＣＭＡに結合する前記第２の結合アームが、（ｉ）それぞれ、配列番号１４３のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨと、（ｉｉ）それぞれ、配列番号１４４のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬと、を含む、上記［４６］に記載の多重特異性ＴＲＧＶ９抗体。
［４８］前記第２の標的が、ＰＳＭＡである、上記［２５］～［３８］又は［４１］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［４９］ＰＳＭＡに結合する前記第２の結合アームが、（ｉ）それぞれ、配列番号７７５のアミノ酸配列を有するＶＨのＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３のアミノ酸配列を有する、ＶＨＣＤＲ１、ＶＨＣＤＲ２、及びＶＨＣＤＲ３を含むＶＨと、（ｉｉ）それぞれ、配列番号７７６のアミノ酸配列を有するＶＬのＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３のアミノ酸配列を有する、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３を含むＶＬと、を含む、上記［４８］に記載の多重特異性ＴＲＧＶ９抗体。
［５０］前記第２の結合アームの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、Ｋａｂａｔ付番システムに従う、上記［４０］、［４３］、［４５］、［４７］、又は［４９］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［５１］前記第２の結合アームの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、Ｃｈｏｔｈｉａ付番システムに従う、上記［４０］、［４３］、［４５］、［４７］、又は［４９］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［５２］前記第２の結合アームの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、ＡｂＭ付番システムに従う、上記［４０］、［４３］、［４５］、［４７］、又は［４９］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［５３］前記第２の結合アームの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、Ｃｏｎｔａｃｔ付番システムに従う、上記［４０］、［４３］、［４５］、［４７］、又は［４９］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［５４］前記第２の結合アームの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、ＩＭＧＴ付番システムに従う、上記［４０］、［４３］、［４５］、［４７］、又は［４９］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［５５］前記第２の結合アームの前記ＶＨＣＤＲ１、ＶＨＣＤＲ２、ＶＨＣＤＲ３、ＶＬＣＤＲ１、ＶＬＣＤＲ２、及びＶＬＣＤＲ３アミノ酸配列が、例示的な付番システムに従う、上記［４０］、［４３］、［４５］、［４７］、又は［４９］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体。
［５６］多重特異性ＴＲＧＶ９抗体であって、Ｔ細胞の表面上でＴＲＧＶ９に結合することができる第１の手段と、ＴＲＧＶ９ではない第２の標的に結合することができる第２の手段と、を含む、多重特異性ＴＲＧＶ９抗体。
［５７］前記第２の標的が、標的細胞の表面上に存在する、上記［５６］に記載の多重特異性ＴＲＧＶ９抗体。
［５８］上記［１］～［５７］のいずれか一項に記載の抗体をコードする、核酸。
［５９］上記［５８］に記載の核酸を含む、ベクター。
［６０］上記［５９］に記載のベクターを含む、宿主細胞。
［６１］上記［５９］に記載のベクターと、そのためのパッケージとを含む、キット。
［６２］上記［１］～［５７］のいずれか一項に記載の抗体と、そのパッケージとを含む、キット。
［６３］上記［１］～［５７］のいずれか一項に記載の抗体と、薬学的に許容される担体と、を含む、医薬組成物。
［６４］上記［６３］に記載の医薬組成物を製造する方法であって、前記抗体を薬学的に許容される担体と組み合わせて、前記医薬組成物を得ることを含む、方法。
［６５］ＴＲＧＶ９を発現するＴ細胞を活性化する方法であって、前記Ｔ細胞を、上記［１］～［５７］のいずれか一項に記載の抗体と接触させることを含む、方法。
［６６］前記接触させることが、ＴＲＧＶ９を発現する対照Ｔ細胞と比較して、ＣＤ６９、ＣＤ２５、及び／又はグランザイムＢ発現の増加をもたらす、上記［６５］に記載の方法。
［６７］２つ以上の標的分子に結合する抗体を作製するためのプロセスであって、前記プロセスが、Ｔ細胞上に存在するＴＲＧＶ９に結合する第１の結合ドメインを得る機能を果たすための工程と、標的細胞の表面上の第２の標的に結合する第２の結合ドメインを得る機能を果たすための工程と、Ｔ細胞上に存在するＴＲＧＶ９及び標的細胞の表面上の第２の標的に結合する抗体を提供する機能を果たすための工程と、を含む、プロセス。
［６８］標的細胞の表面上の第２の標的に結合する第２の結合ドメインを得る機能を果たすための前記工程がｎ回繰り返され、Ｔ細胞上に存在するＴＲＧＶ９及びｎ個の標的分子に結合する第１の結合ドメインを提供する機能を果たすためのｎ個の工程を更に含み、ｎが少なくとも２である、上記［６７］に記載のプロセス。
［６９］ＴＲＧＶ９を発現するＴ細胞を標的細胞に方向付ける方法であって、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体を前記標的細胞と接触させることを含み、前記第２の標的が、前記標的細胞の表面上に存在し、前記接触させることは、前記Ｔ細胞を前記標的細胞に方向付ける、方法。
［７０］標的細胞の成長又は増殖を阻害する方法であって、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体を、前記標的細胞の表面上に前記第２の標的が存在する前記標的細胞と接触させることを含み、前記接触させることが、前記ＴＲＧＶ９を発現するＴ細胞の存在下にあり、前記接触させることは、前記標的細胞の成長又は増殖の阻害をもたらす、方法。
［７１］対象における標的細胞を排除する方法であって、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体を、前記標的細胞の表面上に前記第２の標的が存在する前記標的細胞と接触させることを含み、前記接触させることが、前記ＴＲＧＶ９を発現するＴ細胞の存在下にあり、前記接触させることは、前記標的細胞の排除をもたらす、方法。
［７２］対象における疾患を治療する方法であって、有効量の上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体を前記対象に投与することを含み、前記疾患は、標的細胞の表面上に前記第２の標的が存在する前記標的細胞によって全て又は部分的に引き起こされる、方法。
［７３］前記対象が、ヒトである、上記［７１］又は［７２］に記載の方法。
［７４］前記対象が、前記方法を必要としている対象である、上記［７１］～［７３］のいずれか一項に記載の方法。
［７５］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が癌細胞である、上記［２６］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～７４］のいずれか一項に記載の方法。
［７６］（ｉ）前記癌細胞が、副腎癌、肛門癌、虫垂癌、胆管癌、膀胱癌、骨癌、脳癌、乳癌、子宮頸癌、結腸直腸癌、食道癌、胆嚢癌、妊娠性絨毛、頭頸部癌、ホジキンリンパ腫、腸癌、腎臓癌、白血病、肝臓癌、肺癌、黒色腫、中皮腫、多発性骨髄腫、神経内分泌腫瘍、非ホジキンリンパ腫、口腔癌、卵巣癌、膵臓癌、前立腺癌、副鼻腔癌、皮膚癌、軟部肉腫脊椎癌、胃癌、精巣癌、咽頭癌、甲状腺癌、子宮癌子宮内膜癌、膣癌、又は外陰癌の細胞であり、
（ｉｉ）第２の標的が、アンジオポエチン、ＢＣＭＡ、ＣＤ１９、ＣＤ２０、ＣＤ２２、ＣＤ２５（ＩＬ２－Ｒ）、ＣＤ３０、ＣＤ３３、ＣＤ３７、ＣＤ３８、ＣＤ５２、ＣＤ５６、ＣＤ１２３（ＩＬ－３Ｒ）、ｃＭＥＴ、ＤＬＬ／Ｎｏｔｃｈ、ＥＧＦＲ、ＥｐＣＡＭ、ＦＧＦ、ＦＧＦ－Ｒ、ＧＤ２、ＨＥＲ２、メソテリン、ネクチン－４、ＰＡＰ、ＰＤＧＦＲα、ＰＳＡ、ＰＳＡ３、ＰＳＭＡ、ＲＡＮＫＬ、ＳＬＡＭＦ７、ＳＴＥＡＰ１、ＴＡＲＰ、ＴＲＯＰ２、ＶＥＧＦ、若しくはＶＥＧＦ－Ｒであり、かつ／又は
（ｉｉｉ）前記第２の標的が、ＣＥＡ、未成熟ラミニン受容体、ＴＡＧ－７２、ＨＰＶＥ６、ＨＰＶＥ７、ＢＩＮＧ－４、カルシウム依存性塩素チャネル２、サイクリン－Ｂ１、９Ｄ７、ＥｐＣＡＭ、ＥｐｈＡ３、Ｈｅｒ２／ｎｅｕ、テロメラーゼ、メソテリン、ＳＡＰ－１、サバイビング、ＢＡＧＥファミリー抗原、ＣＡＧＥファミリー抗原、ＧＡＧＥファミリー抗原、ＭＡＧＥファミリー抗原、ＳＡＧＥファミリー抗原、ＸＡＧＥファミリー抗原、ＮＹ－ＥＳＯ－１／ＬＡＧＥ－１、ＰＲＡＭＥ、ＳＳＸ－２、Ｍｅｌａｎ－Ａ、ＭＡＲＴ－１、Ｇｐ１００、ｐｍｅｌ１７、チロシナーゼ、ＴＲＰ－１、ＴＲＰ－２、Ｐ．ポリペプチド、ＭＣ１Ｒ、前立腺特異抗原、β－カテニン、若しくはＢＲＣＡ１である、上記［７５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［７７］前記第２の標的が、ＣＤ１２３である、上記［７５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［７８］前記第２の標的が、ＣＤ３３である、上記［７５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［７９］前記第２の標的が、ＢＣＭＡである、上記［７５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［８０］前記第２の標的が、ＰＳＭＡである、上記［７５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［８１］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞がＴ細胞である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［８２］前記第２の標的が、ＣＤＲ３、ＣＤ１６、ＣＤ１７、ＣＤ１８、ＣＤ２０、ＣＤ２１、ＣＤ２３、ＣＤ２５、ＣＤ２６、ＣＤ２７、ＣＤ２８、ＣＤ２９、ＣＤ３０、ＣＤ３１、ＣＤ３２ｂ、ＣＤ３５、ＣＤ３７、ＣＤ３８、ＣＤ３９、ＣＤ４３、ＣＤ４４、ＣＤ４５、ＣＤ４５ＲＡ、ＣＤ４５ＲＢ、ＣＤ４５ＲＣ、ＣＤ４５ＲＯ、ＣＤ４６、ＣＤ４７、ＣＤ４８、ＣＤ４９ａ、ＣＤ４９ｂ、ＣＤ４９ｃ、ＣＤ４９ｄ、ＣＤ４９ｅ、ＣＤ４９ｆ、ＣＤ５０、ＣＤ５２、ＣＤ５３、ＣＤ５４、ＣＤ５５、ＣＤ５６、ＣＤ５７、ＣＤ５８、ＣＤ５９、ＣＤ６０ａ、ＣＤ６２Ｌ、ＣＤ６３、ＣＤ６８、ＣＤ６９、ＣＤ７０、ＣＤ７１、ＣＤ７３、ＣＤ７４、ＣＤ７５Ｓ、ＣＤ８０、ＣＤ８１、ＣＤ８２、ＣＤ８４、ＣＤ８５Ａ、ＣＤ８５Ｊ、ＣＤ８６、ＣＤ８７、ＣＤ９２、ＣＤ９４、ＣＤ９５、ＣＤ９６、ＣＤ９７、ＣＤ９８、ＣＤ９９、ＣＤ９９Ｒ、ＣＤ１００、ＣＤ１０１、ＣＤ１０２、ＣＤ１０３、ＣＤ１０７ａ、ＣＤ１０７ｂ、ＣＤ１０８、ＣＤ１０９、ＣＤ１１９、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２１ａ、ＣＤ１２１ｂ、ＣＤ１２２、ＣＤ１２４、ＣＤ１２６、ＣＤ１２７、ＣＤ１２８、ＣＤ１２９、ＣＤ１３０、ＣＤ１３２、ＣＤ１３４、ＣＤ１３７、ＣＤ１４６、ＣＤ１４７、ＣＤ１４８、ＣＤ１５０、ＣＤ１５２、ＣＤ１５３、ＣＤ１５４、ＣＤ１５６ｂ、ＣＤ１５８ａ、ＣＤ１５８ｂ１、ＣＤ１５８ｂ２、ＣＤ１５８ｅ１／ｅ２、ＣＤ１５８ｆ、ＣＤ１５８ｇ、ＣＤ１５８ｈ、ＣＤ１５８ｉ、ＣＤ１５８ｊ、ＣＤ１５８ｋ、ＣＤ１５９ａ、ＣＤ１６０、ＣＤ１６１、ＣＤ１６２、ＣＤ１６４、ＣＤ１７２ｇ、ＣＤ１７８、ＣＤ１８１、ＣＤ１８２、ＣＤ１８３、ＣＤ１８４、ＣＤ１８５、ＣＤ１８６、ＣＤ１９１、ＣＤ１９２、ＣＤ１９３、ＣＤ１９４、ＣＤ１９５、ＣＤ１９６、ＣＤ１９７、ＣＤｗ１９８、ＣＤｗ１９９、ＣＤ２０５、ＣＤ２１０ａ、ＣＤｗ２１０ｂ、ＣＤ２１２、ＣＤ２１５、ＣＤ２１７、ＣＤ２１８ａ、ＣＤ２１８ｂ、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２３、ＣＤ２２４、ＣＤ２２５、ＣＤ２２６、ＣＤ２２７、ＣＤ２２９、ＣＤ２３０、ＣＤ２３１、ＣＤ２４４、ＣＤ２４５、ＣＤ２４６、ＣＤ２４７、ＣＤ２５３、ＣＤ２５４、ＣＤ２５５、ＣＤ２５６、ＣＤ２５７、ＣＤ２５８、ＣＤ２５９、ＣＤ２６０、ＣＤ２６１、ＣＤ２６２、ＣＤ２６３、ＣＤ２６４、ＣＤ２６７、ＣＤ２６８、ＣＤ２７０、ＣＤ２７２、ＣＤ２７３、ＣＤ２７４、ＣＤ２７５、ＣＤ２７７、ＣＤ２７８、ＣＤ２７９、ＣＤ２８３、ＣＤ２８８、ＣＤ２８９、ＣＤ２９０、ＣＤ２９４、ＣＤ２９５、ＣＤ２９６、ＣＤ２９８、ＣＤ３００ａ、ＣＤ３００ｃ、ＣＤ３００ｅ、ＣＤ３０５、ＣＤ３０６、ＣＤ３０７ｃ、ＣＤ３１４、ＣＤ３１６、ＣＤ３１７、ＣＤ３１９、ＣＤ３２１、ＣＤ３２８、ＣＤ３５１、ＣＤ３５２、ＣＤ３５２、ＣＤ３５４、ＣＤ３５５、ＣＤ３５７、ＣＤ３５８、ＣＤ３５９、ＣＤ３６０、ＣＤ３６１、ＣＤ３６２、又はＣＤ３６３である、上記［８１］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［８３］前記第２の標的が、ＴＲＢＣ１である、上記［８１］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［８４］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞がＢ細胞である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［８５］前記第２の標的が、ＣＤ１ａ、ＣＤ１ｂ、ＣＤ１ｃ、ＣＤ１ｄ、ＣＤ２、ＣＤ５、ＣＤ６、ＣＤ９、ＣＤ１１ａ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤ１７、ＣＤ１８、ＣＤ１９、ＣＤ２０、ＣＤ２１、ＣＤ２２、ＣＤ２３、ＣＤ２４、ＣＤ２５、ＣＤ２６、ＣＤ２７、ＣＤ２９、ＣＤ３０、ＣＤ３１、ＣＤ３２ａ、ＣＤ３２ｂ、ＣＤ３５、ＣＤ３７、ＣＤ３８、ＣＤ３９、ＣＤ４０、ＣＤ４５、ＣＤ４５ＲＡ、ＣＤ４５ＲＢ、ＣＤ４５ＲＣ、ＣＤ４５ＲＯ、ＣＤ４６、ＣＤ４７、ＣＤ４８、ＣＤ４９ｂ、ＣＤ４９ｃ、ＣＤ４９ｄ、ＣＤ５０、ＣＤ５２、ＣＤ５３、ＣＤ５４、ＣＤ５５、ＣＤ５８、ＣＤ６０ａ、ＣＤ６２Ｌ、ＣＤ６３、ＣＤ６８、ＣＤ６９、ＣＤ７０、ＣＤ７２、ＣＤ７３、ＣＤ７４、ＣＤ７５、ＣＤ７５Ｓ、ＣＤ７７、ＣＤ７９ａ、ＣＤ７９ｂ、ＣＤ８０、ＣＤ８１、ＣＤ８２、ＣＤ８３、ＣＤ８４、ＣＤ８５Ｅ、ＣＤ８５Ｉ、ＣＤ８５Ｊ、ＣＤ８６、ＣＤ９２、ＣＤ９５、ＣＤ９７、ＣＤ９８、ＣＤ９９、ＣＤ１００、ＣＤ１０２、ＣＤ１０８、ＣＤ１１９、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２１ｂ、ＣＤ１２２、ＣＤ１２４、ＣＤ１２５、ＣＤ１２６、ＣＤ１３０、ＣＤ１３２、ＣＤ１３７、ＣＤ１３８、ＣＤ１３９、ＣＤ１４７、ＣＤ１４８、ＣＤ１５０、ＣＤ１５２、ＣＤ１６２、ＣＤ１６４、ＣＤ１６６、ＣＤ１６７ａ、ＣＤ１７０、ＣＤ１７１、ＣＤ１７５、ＣＤ１７５ｓ、ＣＤ１８０、ＣＤ１８４、ＣＤ１８５、ＣＤ１９２、ＣＤ１９６、ＣＤ１９７、ＣＤ２００、ＣＤ２０５、ＣＤ２０１ａ、ＣＤｗ２１０ｂ、ＣＤ２１２、ＣＤ２１３ａ１、ＣＤ２１３ａ２、ＣＤ２１５、ＣＤ２１７、ＣＤ２１８ａ、ＣＤ２１８ｂ、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２４、ＣＤ２２５、ＣＤ２２６、ＣＤ２２７、ＣＤ２２９、ＣＤ２３０、ＣＤ２３２、ＣＤ２５２、ＣＤ２５２、ＣＤ２５４、ＣＤ２５５、ＣＤ２５６、ＣＤ２５７ＣＤ２５８、ＣＤ２５９、ＣＤ２６０、ＣＤ２６１、ＣＤ２６２、ＣＤ２６３、ＣＤ２６４、ＣＤ２６７－２７０、ＣＤ２７２、ＣＤ２７４、ＣＤ２７５、ＣＤ２７７、ＣＤ２７９、ＣＤ２８３、ＣＤ２８９、ＣＤ２９０、ＣＤ２９５、ＣＤ２９８、ＣＤ３００、ＣＤ３００ｃ、ＣＤ３０５、ＣＤ３０６、ＣＤ３０７ａ、ＣＤ３０７ｂ、ＣＤ３０７ｃ、ＣＤ３０７ｄ、ＣＤ３０７ｅ、ＣＤ３１４、ＣＤ２１５、ＣＤ３１６、ＣＤ３１７、ＣＤ３１９、ＣＤ３２１、ＣＤ３２７、ＣＤ３２８、ＣＤ３２９、ＣＤ３３８、ＣＤ３５１、ＣＤ３５２、ＣＤ３５３、ＣＤ３５４、ＣＤ３５５、ＣＤ３５６、ＣＤ３５７、ＣＤ３５８、ＣＤ３６０、ＣＤ３６１、ＣＤ３６２、又はＣＤ３６３である、上記［８４］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［８６］前記第２の標的が、ＢＣＭＡである、上記［８４］に記載の多重特異性ＴＲＧＶ９抗体。
［８７］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が樹状細胞である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［８８］前記第２の標的が、ＣＤ１ａ、ＣＤ１ｂ、ＣＤ１ｃ、ＣＤ１ｄ、ＣＤ１ｅ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤ１６、ＣＤ１７、ＣＤ１８、ＣＤ１９、ＣＤ２１、ＣＤ２３、ＣＤ２９、ＣＤ３３、ＣＤ３５、ＣＤ３６、ＣＤ３８、ＣＤ３９、ＣＤ４０、ＣＤ４５、ＣＤ４５ＲＡ、ＣＤ４５ＲＢ、ＣＤ４５ＲＣ、ＣＤ４５ＲＯ、ＣＤ４８、ＣＤ４９ｄ、ＣＤ４９ｅ、ＣＤ５８、ＣＤ６４ａ、ＣＤ６８、ＣＤ７３、ＣＤ７４、ＣＤ８０、ＣＤ８１、ＣＤ８３、ＣＤ８４、ＣＤ８５Ａ、ＣＤ８５Ｄ、ＣＤ８５Ｅ、ＣＤ８５Ｇ、ＣＤ８５Ｊ、ＣＤ８６、ＣＤ８８、ＣＤ９７、ＣＤ１０１、ＣＤ１１６、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２３、ＣＤ１３９、ＣＤ１４８、ＣＤ１５０、ＣＤ１５６ｂ、ＣＤ１５７、ＣＤ１６７、ＣＤ１６８、ＣＤ１６９、ＣＤ１７０、ＣＤ１７１、ＣＤ１７２ａ、ＣＤ１７２ｂ、ＣＤ１８０、ＣＤ１８４、ＣＤ１８５、ＣＤ１９３、ＣＤ１９６、ＣＤ１９７、ＣＤ２００、ＣＤ２０５、ＣＤ２０６、ＣＤ２０７、ＣＤ２０８、ＣＤ２０９、ＣＤｗ２１０ｂ、ＣＤ２１３ａ１、ＣＤ２１７、ＣＤ２１８ａ、ＣＤ２１８ｂ、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２７、ＣＤ２２９、ＣＤ２３０、ＣＤ２３２、ＣＤ２４４、ＣＤ２５２、ＣＤ２５６、ＣＤ２５７、ＣＤ２５８、ＣＤ２６５、ＣＤ２７０、ＣＤ２７１、ＣＤ２７２、ＣＤ２７３、ＣＤ２７４、ＣＤ２７５、ＣＤ２７６、ＣＤ２７７、ＣＤ２８３、ＣＤ２８６、ＣＤ２８８、ＣＤ２８９、ＣＤ２９０、ＣＤ２９５、ＣＤ２９８、ＣＤ３００ａ、ＣＤ３００ｃ、ＣＤ３００ｅ、ＣＤ３０１、ＣＤ３０２、ＣＤ３０３、ＣＤ３０４、ＣＤ３０５、ＣＤ３１２、ＣＤ３１７、ＣＤ３１９、ＣＤ３２０、ＣＤ３２８、ＣＤ３５２、ＣＤ３５４、ＣＤ３５７、又はＣＤ３６１である、上記［８７］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［８９］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞がＮＫ細胞である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［９０］前記第２の標的が、ＣＤ２、ＣＤ７、ＣＤ８ａ、ＣＤ１０、ＣＤ１１ａ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤｗ１２、ＣＤ１６、ＣＤ１８、ＣＤ２５、ＣＤ２６、ＣＤ２７、ＣＤ２９、ＣＤ３０、ＣＤ３１、ＣＤ３２ｃ、ＣＤ３８、ＣＤ３９、ＣＤ４３、ＣＤ４４、ＣＤ４５、ＣＤ４５ＲＡ、ＣＤ４５ＲＢ、ＣＤ４５ＲＣ、ＣＤ４５ＲＯ、ＣＤ４６、ＣＤ４７、ＣＤ４８、ＣＤ４９ａ、ＣＤ４９ｂ、ＣＤ４９ｄ、ＣＤ４９ｅ、ＣＤ５０、ＣＤ５２、ＣＤ５３、ＣＤ５５、ＣＤ５６、ＣＤ７、ＣＤ５８、ＣＤ５９、ＣＤ６２Ｌ、ＣＤ６３、ＣＤ６９、ＣＤ８１、ＣＤ８２、ＣＤ８４、ＣＤ８５Ｃ、ＣＤ８５Ｅ、ＣＤ８５Ｊ、ＣＤ８７、ＣＤ９４、ＣＤ９５、ＣＤ９６、ＣＤ９７、ＣＤ９８、ＣＤ９９、ＣＤ９９Ｒ、ＣＤ１００、ＣＤ１１９、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２２、ＣＤ１３０、ＣＤ１３２、ＣＤ１４７、ＣＤ１４８、ＣＤ１５８ａ、ＣＤ１５８ｂ１、ＣＤ１５８ｂ２、ＣＤ１５８ｄ、ＣＤ１５８ｅ１／ｅ２、ＣＤ１５８ｆ、ＣＤ１５８ｇ、ＣＤ１５８ｈ、ＣＤ１５８ｉ、ＣＤ１５８ｊ、ＣＤ１５８ｋ、ＣＤ１５９ａ、ＣＤ１５９ｃ、ＣＤ１６０、ＣＤ１６１、ＣＤ１７２ｇ、ＣＤ１７８、ＣＤ１８３、ＣＤ１８５、ＣＤｗ２１０ｂ、ＣＤ２１２、ＣＤ２１７、ＣＤ２１８ａ、ＣＤ２１８ｂ、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２３、ＣＤ２２５、ＣＤ２２６、ＣＤ２２９、ＣＤ２３０、ＣＤ２３２、ＣＤ２４４、ＣＤ２４７、ＣＤ２５７、ＣＤ２６１、ＣＤ２６２、ＣＤ２６３、ＣＤ２６４、ＣＤ２７０、ＣＤ２７７、ＣＤ２８０、ＣＤ２９５、ＣＤ２９８、ＣＤ３０５、ＣＤ３１４、ＣＤ３１６、ＣＤ３１７、ＣＤ３１９、ＣＤ３２１、ＣＤ３２８、ＣＤ３２９、ＣＤ３３５、ＣＤ３３６、ＣＤ３３７、ＣＤ３５２、ＣＤ３５４、ＣＤ３５５、ＣＤ３５７、ＣＤ３６０、ＣＤ３６１、又はＣＤ３６３である、上記［８９］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［９１］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が幹細胞又は幹細胞前駆体である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［９２］前記第２の標的が、ＣＤ８ａ、ＣＤｗ１２、ＣＤ１３、ＣＤ１５、ＣＤ１９、ＣＤ２１、ＣＤ２２、ＣＤ２９、ＣＤ３０、ＣＤ３３、ＣＤ３４、ＣＤ３６、ＣＤ３８、ＣＤ４０、ＣＤ４１、ＣＤ４２ａ、ＣＤ４２ｂ、ＣＤ４２ｃ、ＣＤ４２ｄ、ＣＤ４３、ＣＤ４５、ＣＤ４５ＲＡ、ＣＤ４５ＲＢ、ＣＤ４５ＲＣ、ＣＤ４５ＲＯ、ＣＤ４８、ＣＤ４９ｂ、ＣＤ４９ｄ、ＣＤ４９ｅ、ＣＤ４９ｆ、ＣＤ５０、ＣＤ５３、ＣＤ５５、ＣＤ６４ａ、ＣＤ６８、ＣＤ７１、ＣＤ７２、ＣＤ７３、ＣＤ８１、ＣＤ８２、ＣＤ８５Ａ、ＣＤ８５Ｋ、ＣＤ９０、ＣＤ９９、ＣＤ１０４、ＣＤ１０５、ＣＤ１０９、ＣＤ１１０、ＣＤ１１１、ＣＤ１１２、ＣＤ１１４、ＣＤ１１５、ＣＤ１１７、ＣＤ１２３、ＣＤ１２４、ＣＤ１２６、ＣＤ１２７、ＣＤ１３０、ＣＤ１３１、ＣＤ１３３、ＣＤ１３５、ＣＤ１３８、ＣＤ１５１、ＣＤ１５７、ＣＤ１６２、ＣＤ１６４、ＣＤ１６８、ＣＤ１７２ａ、ＣＤ１７３、ＣＤ１７４、ＣＤ１７５、ＣＤ１７５ｓ、ＣＤ１７６、ＣＤ１８３、ＣＤ１９１、ＣＤ２００、ＣＤ２０１、ＣＤ２０５、ＣＤ２１７、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２４、ＣＤ２２５、ＣＤ２２６、ＣＤ２２７、ＣＤ２２８、ＣＤ２２９、ＣＤ２３０、ＣＤ２３５ａ、ＣＤ２３５ｂ、ＣＤ２３６、ＣＤ２３６Ｒ、ＣＤ２３８、ＣＤ２４０、ＣＤ２４２、ＣＤ２４３、ＣＤ２７７、ＣＤ２９２、ＣＤｗ２９３、ＣＤ２９５、ＣＤ２９８、ＣＤ３０９、ＣＤ３１８、ＣＤ３２４、ＣＤ３２５、ＣＤ３３８、ＣＤ３４４、ＣＤ３４９、又はＣＤ３５０である、上記［９１］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［９３］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が単球又はマクロファージである、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［９４］前記第２の標的が、ＣＤ１ａ、ＣＤ１ｂ、ＣＤ１ｃ、ＣＤ４、ＣＤ９、ＣＤ１１ａ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤ１１ｄ、ＣＤｗ１２、ＣＤ１３、ＣＤ１４、ＣＤ１５、ＣＤ１６、ＣＤ１７、ＣＤ１８、ＣＤ２３、ＣＤ２５、ＣＤ２６、ＣＤ２９、ＣＤ３０、ＣＤ３１、ＣＤ３２ａ、ＣＤ３２ｂ、ＣＤ３２ｃ、ＣＤ３３、ＣＤ３５、ＣＤ３６、ＣＤ３７、ＣＤ３８、ＣＤ３９、ＣＤ４０、ＣＤ４４、ＣＤ４５、ＣＤ４５ＲＡ、ＣＤ４５ＲＢ、ＣＤ４５ＲＣ、ＣＤ４５ＲＯ、ＣＤ４６、ＣＤ４７、ＣＤ４８、ＣＤ４９ａ、ＣＤ４９ｂ、ＣＤ４９ｃ、ＣＤ４９ｄ、ＣＤ４９ｅ、ＣＤ４９ｆ、ＣＤ５０、ＣＤ５１、ＣＤ５２、ＣＤ５３、ＣＤ５４、ＣＤ５５、ＣＤ５８、ＣＤ５９、ＣＤ６０ａ、ＣＤ６１、ＣＤ６３、ＣＤ６４ａ、ＣＤ６５、ＣＤ６６、ＣＤ６８、ＣＤ６９、ＣＤ７２、ＣＤ７４、ＣＤ７５、ＣＤ７５Ｓ、ＣＤ８０、ＣＤ８１、ＣＤ８２、ＣＤ８４、ＣＤ８５Ａ、ＣＤ８５Ｃ、ＣＤ８５Ｄ、ＣＤ８５Ｅ、ＣＤ８５Ｆ、ＣＤ８５Ｇ、ＣＤ８５Ｉ、ＣＤ８５Ｊ、ＣＤ８５Ｋ、ＣＤ８６、ＣＤ８７、ＣＤ８８、ＣＤ８９、ＣＤ９１、ＣＤ９２、ＣＤ９３、ＣＤ９５、ＣＤ９７、ＣＤ９８、ＣＤ９９、ＣＤ９９Ｒ、ＣＤ１００、ＣＤ１０１、ＣＤ１０２、ＣＤ１０５、ＣＤ１１１、ＣＤ１１２、ＣＤ１１４、ＣＤ１１５、ＣＤ１１６、ＣＤ１１９、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２１ｂ、ＣＤ１２２、ＣＤ１２４、ＣＤ１２７、ＣＤ１３０、ＣＤ１３１、ＣＤ１３２、ＣＤ１３６、ＣＤ１３７、ＣＤ１３９、ＣＤ１４１、ＣＤ１４２、ＣＤ１４３、ＣＤ１４７、ＣＤ１４８、ＣＤ１５３、ＣＤ１５５、ＣＤ１５６ａ、ＣＤ１５６ｂ、ＣＤ１５６ｃ、ＣＤ１５７、ＣＤ１６２、ＣＤ１６３、ＣＤ１６４、ＣＤ１６５、ＣＤ１６６、ＣＤ１６８、ＣＤ１６９、ＣＤ１７０、ＣＤ１７１、ＣＤ１７２ａ、ＣＤ１７２ｂ、ＣＤ１８０、ＣＤ１８１、ＣＤ１８２、ＣＤ１８４、ＣＤ１８５、ＣＤ１９１、ＣＤ１９２、ＣＤ１９４、ＣＤ１９５、ＣＤｗ１９８、ＣＤ２４、ＣＤ２０５、ＣＤ２０６、ＣＤ２０９、ＣＤ２１０ａ、ＣＤｗ２１０ｂ、ＣＤ２１３ａ１、ＣＤ２１３ａ２、ＣＤ２１７、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２４、ＣＤ２２６、ＣＤ２２７、ＣＤ２３０、ＣＤ２３２、ＣＤ２４４、ＣＤ２５２、ＣＤ２５６、ＣＤ２５７、ＣＤ２５８、ＣＤ２６１、ＣＤ２６２、ＣＤ２６３、ＣＤ２６４、ＣＤ２６５、ＣＤ２６７、ＣＤ２６８、ＣＤ２７０、ＣＤ２７２、ＣＤ２７３、ＣＤ２７４、ＣＤ２７５、ＣＤ２７６、ＣＤ２７７、ＣＤ２８０、ＣＤ２８１、ＣＤ２８２、ＣＤ２８４、ＣＤ２８６、ＣＤ２８８、ＣＤ２８９、ＣＤ２９５、ＣＤ２９７、ＣＤ２９８、ＣＤ３００ａ、ＣＤ３００ｃ、ＣＤ３００ｅ、ＣＤ３０１、ＣＤ３０２、ＣＤ３０５、ＣＤ３０６、ＣＤ３１２、ＣＤ２１４、ＣＤ３１５、ＣＤ３１７、ＣＤ３１９、ＣＤ３２１、ＣＤ３２８、ＣＤ３２９、ＣＤ３３８、ＣＤ３５１、ＣＤ３５２、ＣＤ３５２、ＣＤ３５４、ＣＤ３５７、ＣＤ３５８、ＣＤ３６０、ＣＤ３６１、又はＣＤ３６２である、上記［９３］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［９５］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が顆粒球である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［９６］前記第２の標的が、ＣＤ１１ａ、ＣＤ１１ｂ、ＣＤ１１ｃ、ＣＤｗ１２、ＣＤ１３、ＣＤ１４、ＣＤ１５、ＣＤ１６、ＣＤ１６ｂ、ＣＤ１７、ＣＤ１８、ＣＤ２３、ＣＤ２４、ＣＤ２９、ＣＤ３１、ＣＤ３２ａ、ＣＤ３２ｂ、ＣＤ３２ｃ、ＣＤ３３、ＣＤ３５、ＣＤ３７、ＣＤ４３、ＣＤ４４、ＣＤ４５、ＣＤ４５ＲＢ、ＣＤ４５ＲＯ、ＣＤ４６、ＣＤ４７、ＣＤ５０、ＣＤ５３、ＣＤ５５、ＣＤ５８、ＣＤ５９、ＣＤ６０ａ、ＣＤ６２Ｌ、ＣＤ６３、ＣＤ６４ａ、ＣＤ６５、ＣＤ６５ｓ、ＣＤ６６ａ、ＣＤ６６ｂ、ＣＤ６６ｃ、ＣＤ６６ｄ、ＣＤ６８、ＣＤ６９、ＣＤ７５Ｓ、ＣＤ８２、ＣＤ８５Ａ、ＣＤ８５Ｄ、ＣＤ８５Ｋ、ＣＤ８７、ＣＤ８８、ＣＤ８９、ＣＤ９２、ＣＤ９３、ＣＤ９５、ＣＤ９７、ＣＤ９８、ＣＤ１００、ＣＤ１０１、ＣＤ１０７ａ、ＣＤ１０７ｂ、ＣＤ１１４、ＣＤ１１６、ＣＤ１１９、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２３、ＣＤ１２５、ＣＤ１３０、ＣＤ１３１、ＣＤ１３２、ＣＤ１３９、ＣＤ１４１、ＣＤ１４７、ＣＤ１４８、ＣＤ１５３、ＣＤ１５６ａ、ＣＤ１５６ｂ、ＣＤ１５７、ＣＤ１６２、ＣＤ１７０、ＣＤ１７１、ＣＤ１７２ａ、ＣＤ１７７、ＣＤ１７８、ＣＤ１８１、ＣＤ１８２、ＣＤ１８３、ＣＤ１９２、ＣＤ１９３、ＣＤ１９５、ＣＤ２０３ｃ、ＣＤ２１７、ＣＤ２１８ａ、ＣＤ２１８ｂ、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２３０、ＣＤ２３２、ＣＤ２４４、ＣＤ２５６、ＣＤ２５７、ＣＤ２５８、ＣＤ２６１、ＣＤ２６２、ＣＤ２６３、ＣＤ２６４、ＣＤ２６８、ＣＤ２７０、ＣＤ２７４、ＣＤ２７５、ＣＤ２８１、ＣＤ２８２、ＣＤ２８９、ＣＤ２９０、ＣＤ２９４、ＣＤ２９５、ＣＤ２９８、ＣＤ３０２、ＣＤ３０５、ＣＤ３１２、ＣＤ３１４、ＣＤ３２１、ＣＤ３２８、ＣＤ３２９、ＣＤ３５２、ＣＤ３５４、ＣＤ３６０、又はＣＤ３６２である、上記［９５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［９７］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が血小板である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［９８］前記第２の標的が、ＣＤ９、ＣＤ１７、ＣＤ１８、ＣＤ２３、ＣＤ２９、ＣＤ３１、ＣＤ３２ａ、ＣＤ３２ｂ、ＣＤ３６、ＣＤ４１、ＣＤ４２ａ、ＣＤ４２ｂ、ＣＤ４２ｃ、ＣＤ４２ｄ、ＣＤ４３、ＣＤ４６、ＣＤ４７、ＣＤ６２Ｐ、ＣＤ６３、ＣＤ６９、ＣＤ８２、ＣＤ８４、ＣＤ９８、ＣＤ９９、ＣＤ１０７ａ、ＣＤ１０７ｂ、ＣＤ１０９、ＣＤ１１０、ＣＤ１１１、ＣＤ１１２、ＣＤ１１４、ＣＤ１４０ａ、ＣＤ１４１、ＣＤ１４７、ＣＤ１４８、ＣＤ１５１、ＣＤ１６５、ＣＤ１９４、ＣＤ２２６、ＣＤ２９５、ＣＤ２９８、又はＣＤ３２１である、上記［９７］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［９９］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が赤血球である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［１００］前記第２の標的が、ＣＤ３５、ＣＤ３６、ＣＤ４４、ＣＤ４７、ＣＤ４９ｅ、ＣＤ５５、ＣＤ５８、ＣＤ５９、ＣＤ７５Ｓ、ＣＤ９９、ＣＤ１０８、ＣＤ１１１、ＣＤ１３９、ＣＤ１４７、ＣＤ１７３、ＣＤ１７６、ＣＤ２３３、ＣＤ２３４、ＣＤ２３５ａ、ＣＤ２３５ｂ、ＣＤ２３６、ＣＤ２３６Ｒ、ＣＤ２３８、ＣＤ２３９、ＣＤ２４０、ＣＤ２４１、ＣＤ２４２、又はＣＤ３２４である、上記［９９］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１０１］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が内皮細胞である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［１０２］前記第２の標的が、ＣＤ９、ＣＤ１０、ＣＤ１３、ＣＤ１７、ＣＤ２９、ＣＤ３０、ＣＤ３１、ＣＤ３２ｂ、ＣＤ３４、ＣＤ３６、ＣＤ３９、ＣＤ４０、ＣＤ４４、ＣＤ４６、ＣＤ４７、ＣＤ４９ｂ、ＣＤ４９ｃ、ＣＤ４９ｄ、ＣＤ４ｅ、ＣＤ４９ｆ、ＣＤ５０、ＣＤ５１、ＣＤ５４、ＣＤ５、ＣＤ５８、ＣＤ６１、ＣＤ６２Ｅ、ＣＤ６２Ｐ、ＣＤ６３、ＣＤ７１、ＣＤ７３、ＣＤ７４、ＣＤ７５Ｓ、ＣＤ７７、ＣＤ８１、ＣＤ８２、ＣＤ８６、ＣＤ８７、ＣＤ８８、ＣＤ９０、ＣＤ９２、ＣＤ９３、ＣＤ９８、ＣＤ９９、ＣＤ１０２、ＣＤ１０４、ＣＤ１０５、ＣＤ１０６、ＣＤ１０７ａ、ＣＤ１０７ｂ、ＣＤ１０９、ＣＤ１１０、ＣＤ１１１、ＣＤ１１２、ＣＤ１１４、ＣＤ１１７、ＣＤ１１９、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２１ａ、ＣＤ１２３、ＣＤ１３０、ＣＤ１３３、ＣＤ１３８、ＣＤ１４０ａ、ＣＤ１４０ｂ、ＣＤ１４１、ＣＤ１４２、ＣＤ１４３、ＣＤ１４４、ＣＤｗ１５４、ＣＤ１４６、ＣＤ１４７、ＣＤ１５０、ＣＤ１５１、ＣＤ１５６ｂ、ＣＤ１５７、ＣＤ１６６、ＣＤ１７１、ＣＤ１７３、ＣＤ１７５Ｓ、ＣＤ１７６、ＣＤ１７８、ＣＤ１８４、ＣＤ１９２、ＣＤ２００、ＣＤ２０１、ＣＤ２０２ｂ、ＣＤ２０６、ＣＤ２０９、ＣＤ２１３ａ１、ＣＤ２１７、ＣＤ２１８ａ、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２４、ＣＤ２２５、ＣＤ２２８、ＣＤ２３０、ＣＤ２３４、ＣＤ２３９、ＣＤ２４２、ＣＤ２４６、ＣＤ２４８、ＣＤ２５２、ＣＤ２６６、ＣＤ２８０、２９５、ＣＤ２９７、ＣＤ２９９、ＣＤ３０９、ＣＤ３２１、ＣＤ３２２、又はＣＤ３４４である、上記［１０１］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１０３］前記第２の標的が標的細胞の表面上に存在し、前記標的細胞が上皮細胞である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［１０４］前記第２の標的が、ＣＤ１ｄ、ＣＤ９、ＣＤ１３、ＣＤ１８、ＣＤ２１、ＣＤ２３、ＣＤ２４、ＣＤ２６、ＣＤ２９、ＣＤ３９、ＣＤ４０、ＣＤ４４、ＣＤ４６、ＣＤ４７、ＣＤ４９ｂ、ＣＤ４９ｃ、ＣＤ４９ｅ、ＣＤ４９ｆ、ＣＤ５２、ＣＤ５５、ＣＤ５８、ＣＤ６６ａ、ＣＤ６６ｃ、ＣＤ６６ｅ、ＣＤ６６ｆ、ＣＤ７３、ＣＤ７４、ＣＤ７５Ｓ、ＣＤ７７、ＣＤ８１、ＣＤ８２、ＣＤ８８、９１、ＣＤ９２、ＣＤ９８、ＣＤ９９、ＣＤ１０４、ＣＤ１１０、ＣＤ１１１、ＣＤ１１２、ＣＤ１１３、ＣＤ１１４、ＣＤ１１８、ＣＤ１２０ａ、ＣＤ１２０ｂ、ＣＤ１２４、ＣＤ１２９、ＣＤ１３３、ＣＤ１３６、ＣＤ１３７、ＣＤ１３８、ＣＤ１４１、ＣＤ１４２、ＣＤ１４３、ＣＤｗ１４５、ＣＤ１５１、ＣＤ１６４、ＣＤ１６５、ＣＤ１６６、ＣＤ１６７ａ、ＣＤ１７１、ＣＤ１７４、ＣＤ１７５、ＣＤ１７５Ｓ、ＣＤ１７６、ＣＤ１７８、ＣＤ１９３、ＣＤ２０６、ＣＤ２１３ａ２、ＣＤ２１７、ＣＤ２２０、ＣＤ２２１、ＣＤ２２２、ＣＤ２２４、ＣＤ２２７、ＣＤ２３０、ＣＤ２３４、ＣＤ２３９、ＣＤ２４９、ＣＤ２８６、ＣＤ２９５、ＣＤ２９６、ＣＤ３２１、ＣＤ３２４、ＣＤ３２６、ＣＤ３３１、ＣＤ３３２、ＣＤ３３３、ＣＤ３３４、ＣＤ３３９、ＣＤ３４０、ＣＤ３４４、又はＣＤ３５０である、上記［１０３］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１０５］前記第２の標的が病原体であり、任意選択で前記標的細胞は、前記標的細胞の表面上に病原体抗原を有する細胞である、上記［２５］～［５７］のいずれか一項に記載の多重特異性ＴＲＧＶ９抗体、又は上記［６９］～［７４］のいずれか一項に記載の方法。
［１０６］前記病原体が、ウイルスである、上記［１０５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１０７］前記ウイルスが、アデノウイルス科、アレナウイルス科、アストロウイルス科、ブニヤウイルス科、カリシウイルス科、コロナウイルス科、フィロウイルス科、フラビウイルス科、ヘパドナウイルス科、ヘペウイルス科、オルトミクソウイルス科、パピローマウイルス科、パラミクソウイルス科、パルボウイルス科、ピコルナウイルス科、ポリオーマウイルス科、ポックスウイルス科、レオウイルス科、レトロウイルス科、ラブドウイルス科、又はトガウイルス科のウイルスである、上記［１０６］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１０８］前記ウイルスが、アデノウイルス、コロナウイルス、コクサッキーウイルス、エプスタインバーウイルス、Ａ型肝炎ウイルス、Ｂ型肝炎ウイルス、Ｃ型肝炎ウイルス、単純ヘルペスウイルス２型、サイトメガロウイルス、ヒトヘルペスウイルス８型、ヒト免疫不全ウイルス、インフルエンザウイルス、麻疹ウイルス、ムンプスウイルス、ヒトパピローマウイルス、パラインフルエンザウイルス、ポリオウイルス、狂犬病ウイルス、呼吸器合胞体ウイルス、風疹ウイルス、又は水痘帯状疱疹ウイルスである、上記［１０６］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１０９］前記病原体が、細菌である、上記［１０５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１１０］前記細菌が、バチルス、バルトネラ、ボルデテラ、ボレリア、ブルセラ、カンピロバクター、クラミジア、クラミドフィラ、クロストリジウム、コリネバクテリウム、エンテロコッカス、エシェリキア、フランシセラ、ヘモフィルス、ヘリコバクター、レジオネラ、レプトスピラ、リステリア、マイコバクテリア、マイコプラズマ、ナイセリア、シュードモナス、リケッチア、サルモネラ、シゲラ、ブドウ球菌、連鎖球菌、トレポネーマ、ウレアプラズマ、ビブリオ、又はエルシニア属の細菌である、上記［１０９］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１１１］前記病原体が寄生虫である、上記［１０５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１１２］前記寄生虫が、原虫、蠕虫、又は外部寄生虫である、上記［１１１］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１１３］（ｉ）前記原虫が、エントアメーバ属、ジアルジア属、リーシュマニア属、バランチジウム属、プラスモジウム属、若しくはクリプトスポリジウム属であるか、
（ｉｉ）前記蠕虫が、吸虫、条虫、鈎頭虫、若しくは回虫であるか、又は
（ｉｉｉ）前記外部寄生虫が、節足動物である、上記［１１２］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
［１１４］前記病原体が、急性弛緩性脊髄炎（ＡＦＭ）、アナプラズマ病、炭疽病、バベシア症、ボツリヌス中毒症、ブルセラ症、カンピロバクター症、カルバペネム耐性感染、軟性下疳、チクングニアウイルス感染症、クラミジア、シガテラ中毒、ディフィシル感染症、パーフリンジェンス、コクシジオイデス症真菌感染症、コロナウイルス感染症、Ｃｏｖｉｄ－１９（ＳＡＲＳ－ＣｏＶ－２）、クロイツフェルト・ヤコブ病／伝達性海綿状脳症、クリプトスポリジウム症（Ｃｒｙｐｔｏ）、シクロスポラ症、デング熱１、２、３、又は４、ジフテリア、大腸菌感染症／志賀毒素産生性（ＳＴＥＣ）、東部馬脳炎、出血熱（エボラ）、エーリキア症、アルボウイルス又は傍感染性脳炎、非ポリオエンテロウイルス、Ｄ６８エンテロウイル（ＥＶ－Ｄ６８）、ジアルジア症、鼻疽、淋菌感染症、鼠径部肉芽腫、ヘモフィルスインフルエンザ感染症Ｂ型（Ｈｉｂ又はＨ－ｆｌｕ）、ハンタウイルス肺症候群（ＨＰＳ）、溶血性尿毒症症候群（ＨＵＳ）、Ａ型肝炎（ＨｅｐＡ）、Ｂ型肝炎（ＨｅｐＢ）、Ｃ型肝炎（ＨｅｐＣ）、Ｄ型肝炎（ＨｅｐＤ）、Ｅ型肝炎（ＨｅｐＥ）、ヘルペス、帯状ヘルペス（帯状疱疹）、ヒストプラスマ症、ヒト免疫不全ウイルス／ＡＩＤＳ（ＨＩＶ／ＡＩＤＳ）、ヒトパピローマウイルス（ＨＰＶ）、インフルエンザ（Ｆｌｕ）、レジオネラ症（レジオネラ病）、癩（ハンセン病）、レプトスピラ症、リステリア症（リステリア）、ライム病、鼠径リンパ肉芽腫感染症（ＬＧＶ）、マラリア、麻疹、メリオイドーシス、髄膜炎（ウイルス性）、髄膜炎菌性疾患（髄膜炎（細菌性））、中東呼吸器症候群コロナウイルス（ＭＥＲＳ－ＣｏＶ）、ムンプス、ノロウイルス、シラミ寄生症、骨盤内感染症（ＰＩＤ）、パーツシス（百日咳）、ペスト（腺、敗血性、肺炎性）、肺炎球菌疾患（肺炎）、ポリオウイルス感染症（ポリオ）、ポワッサン、オウム病、シラミ寄生症、膿疱疹疾患（天然痘、サル痘、牛痘）、Ｑ熱、狂犬病、リケッチア症（ロッキー山紅斑熱）、風疹（ドイツ麻疹）、サルモネラ症胃腸炎（サルモネラ）、疥癬、スコンブロイド、敗血症、重症急性呼吸器症候群（ＳＡＲＳ）、赤痢菌感染症胃腸炎（シゲラ）、天然痘、メチシリン耐性スタフィロカル感染症（ＭＲＳＡ）、ブドウ球菌食中毒エンテロトキシンＢ中毒（ブドウ球菌食中毒）、バンコマイシン中間体サフィロコカル感染症（ＶＩＳＡ）、バンコマイシン耐性ブドウ球菌感染症（ＶＲＳＡ）、Ａ群連鎖球菌感染症（侵襲性）（ＳｔｒｅｐＡ（侵襲性）、Ｂ群連鎖球菌感染症（Ｓｔｒｅｐ－Ｂ）、連鎖球菌毒素性ショック症候群ＳＴＳＳ毒素ショック、梅毒（第１期、第２期、早期潜伏、晩期潜伏、先天性）、破傷風感染、トリコモナス症、トリコノシス感染症、結核（ＴＢ）、潜伏性結核（ＬＴＢＩ）、ツラレミア、腸チフスＤ群、膣症、水痘（水疱瘡）、コレラ菌（コレラ）、ビブリオ症（ビブリオ）、エボラウイルス出血熱、ラサウイルス出血熱、マールブルグウイルス出血熱、ウエストナイルウイルス、黄熱、エルセニア、及びジカウイルス感染症からなる群から選択される感染症を引き起こす、上記［１０５］に記載の多重特異性ＴＲＧＶ９抗体又は方法。
Those skilled in the art will appreciate that changes can be made to the embodiments described above without departing from the broader inventive concept. It is therefore understood that this invention is not limited to the particular embodiments disclosed, but is intended to cover modifications within the spirit and scope of the invention as defined by this description.

The following aspects may be included.
[1] An antibody that binds to T cell receptor gamma variable 9 (TRGV9),
(1) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 105;
(2) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 113, and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 114;
(3) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NO: 123, and (ii) or
(4) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 133, and (ii) An antibody comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 134.
[2] The antibody according to [1] above, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences follow the Kabat numbering system.
[3] The antibody according to [1] above, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences follow the Chothia numbering system.
[4] The antibody according to [1] above, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences follow the AbM numbering system.
[5] The antibody according to [1] above, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences follow the Contact numbering system.
[6] The antibody according to [1] above, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences follow the IMGT numbering system.
[7] The antibody according to [1] above, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences follow an exemplary numbering system.
[8] The antibody according to any one of [1] to [7] above, wherein the antibody is a humanized antibody.
[9] The antibody according to any one of [1] to [8] above, wherein the antibody is an IgG antibody.
[10] The antibody according to [9] above, wherein the IgG antibody is an IgG1, IgG2, IgG3, or IgG4 antibody.
[11] The antibody according to any one of [1] to [10] above, wherein the antibody comprises a κ light chain.
[12] The antibody according to any one of [1] to [10] above, wherein the antibody comprises a λ light chain.
[13] The antibody according to any one of [1] to [12] above, wherein the antibody is a monoclonal antibody.
[14] The antibody according to any one of [1] to [13] above, wherein the antibody binds to the TRGV9 antigen.
[15] The antibody according to any one of [1] to [13] above, which binds to a TRGV9 epitope.
[16] The antibody according to any one of [1] to [15] above, wherein the antibody specifically binds to TRGV9.
[17] The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for the TRGV9 antigen, according to any one of [1] to [16] above. antibodies.
[18] The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 form a binding site for the epitope of TRGV9, according to any one of [1] to [16] above. antibodies.
[19] The antibody according to any one of [1] to [18] above, wherein the TRGV9 is present on the surface of T cells.
[20] The antibody according to any one of [1] to [19] above, wherein the antibody is multivalent.
[21] The antibody according to [20] above, wherein the antibody is capable of binding to at least three antigens.
[22] The antibody according to [20] above, wherein the antibody is capable of binding to at least four antigens.
[23] The antibody according to [20] above, wherein the antibody is capable of binding to at least five antigens.
[24] The antibody according to any one of [1] to [23] above, wherein the antibody is a multispecific antibody.
[25] A multispecific TRGV9 antibody, comprising:
(a) a first binding domain that binds to TRGV9, wherein the first binding domain comprises the TRGV9 antibody according to any one of [1] to [23] above;
(b) a second binding domain that binds to a second target that is not TRGV9.
[26] The multispecific TRGV9 antibody according to [25] above, wherein the antibody is a bispecific antibody.
[27] The multispecific TRGV9 antibody according to [25] above, wherein the antibody is a trispecific antibody.
[28] The multispecific TRGV9 antibody according to [25] above, wherein the antibody is a tetraspecific antibody.
[29] The multispecific TRGV9 antibody according to any one of [25] to [28] above, wherein the second binding domain binds to the second target antigen.
[30] The multispecific TRGV9 antibody according to any one of [25] to [28] above, wherein the second binding domain binds to an epitope of the second target.
[31] The multispecific TRGV9 antibody according to any one of [25] to [30] above, wherein the second binding domain specifically binds to the second target.
[32] The above-mentioned [25]-, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of the second binding domain form a binding site for the second target antigen. The multispecific TRGV9 antibody according to any one of [31].
[33] The above [25]-, wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 of the second binding domain form a binding site for the epitope of the second target. The multispecific TRGV9 antibody according to any one of [31].
[34] The multispecific TRGV9 antibody according to any one of [25] to [33] above, wherein the second target is present on the surface of a target cell.
[35] The multispecific TRGV9 antibody according to any one of [25] to [34] above, wherein the second binding domain that binds to the second target is multivalent.
[36] The multispecific TRGV9 antibody according to [35] above, wherein the second binding domain is capable of binding to at least three antigens.
[37] The multispecific TRGV9 antibody according to [35] above, wherein the second binding domain is capable of binding to at least four antigens.
[38] The multispecific TRGV9 antibody according to [35] above, wherein the second binding domain is capable of binding to at least five antigens.
[39] The multispecific TRGV9 antibody according to any one of [25] to [38] above, wherein the second target is CD123.
[40] the second binding arm that binds to CD123: (i) VH CDR1, VH CDR2, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NO: 15; and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 16. The multispecific TRGV9 antibody according to [39] above, comprising:
[41] A multispecific TRGV9 antibody, comprising:
(a) a first binding domain that binds to TRGV9, wherein the first binding domain comprises:
(1) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 7, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 8;
(2) (i) VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of SEQ ID NO: 34; and (ii) each of the sequences A VL comprising VL CDR1, VL CDR2, and VL CDR3, having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of the light chain variable region (VL) having the amino acid sequence number 8;
(3) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 35, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 8;
(4) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 36, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 8;
(5) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 65, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 66;
(6) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 67, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 68, or
(7) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 95, and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 96;
(b) a second binding domain that binds to a second target that is CD33, TRBC1, BCMA, or PSMA.
[42] The multispecific TRGV9 antibody according to any one of [25] to [35] or [41] above, wherein the second target is CD33.
[43] The second binding arm that binds to CD33 has (i) VH CDR1, VH CDR2, and VH CDR2, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NO: 43; , and VH CDR3, and (ii) VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 44. The multispecific TRGV9 antibody according to [42] above, comprising VL.
[44] The multispecific TRGV9 antibody according to any one of [25] to [38] or [41] above, wherein the second target is TRBC1.
[45] The second binding arm that binds to TRBC1 comprises (i) VH CDR1, VH CDR2, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 55; and (ii) VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 56. The multispecific TRGV9 antibody according to [44] above, comprising VL.
[46] The multispecific TRGV9 antibody according to any one of [25] to [38] or [41] above, wherein the second target is BCMA.
[47] The second binding arm that binds to BCMA comprises (i) VH CDR1, VH CDR2, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 143; and (ii) VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 144. The multispecific TRGV9 antibody according to [46] above, comprising VL.
[48] The multispecific TRGV9 antibody according to any one of [25] to [38] or [41] above, wherein the second target is PSMA.
[49] The second binding arm that binds to PSMA comprises (i) VH CDR1, VH CDR2, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 775; , and (ii) VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 776. The multispecific TRGV9 antibody according to [48] above, comprising VL.
[50] The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the Kabat numbering system [40], [43], [45] ], [47], or the multispecific TRGV9 antibody according to any one of [49].
[51] The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the Chothia numbering system [40], [43], [45] ], [47], or the multispecific TRGV9 antibody according to any one of [49].
[52] The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm follow the AbM numbering system [40], [43], [45] ], [47], or the multispecific TRGV9 antibody according to any one of [49].
[53] The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm follow the Contact numbering system [40], [43], [45] ], [47], or the multispecific TRGV9 antibody according to any one of [49].
[54] The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm are according to the IMGT numbering system [40], [43], [45] ], [47], or the multispecific TRGV9 antibody according to any one of [49].
[55] wherein the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 amino acid sequences of the second binding arm follow an exemplary numbering system [40], [43], The multispecific TRGV9 antibody according to any one of [45], [47], or [49].
[56] a multispecific TRGV9 antibody, a first means capable of binding to TRGV9 on the surface of a T cell, and a second means capable of binding to a second target that is not TRGV9; A multispecific TRGV9 antibody comprising:
[57] The multispecific TRGV9 antibody according to [56] above, wherein the second target is present on the surface of a target cell.
[58] A nucleic acid encoding the antibody according to any one of [1] to [57] above.
[59] A vector comprising the nucleic acid according to [58] above.
[60] A host cell comprising the vector described in [59] above.
[61] A kit comprising the vector described in [59] above and a package therefor.
[62] A kit comprising the antibody according to any one of [1] to [57] above and a package thereof.
[63] A pharmaceutical composition comprising the antibody according to any one of [1] to [57] above and a pharmaceutically acceptable carrier.
[64] A method for producing the pharmaceutical composition according to [63] above, which comprises combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.
[65] A method for activating T cells expressing TRGV9, the method comprising contacting the T cells with the antibody according to any one of [1] to [57] above.
[66] The method according to [65] above, wherein the contacting results in increased expression of CD69, CD25, and/or granzyme B compared to control T cells expressing TRGV9.
[67] A process for producing an antibody that binds to two or more target molecules, the process functioning to obtain a first binding domain that binds to TRGV9 present on a T cell. and a step for performing the function of obtaining a second binding domain that binds to a second target on the surface of the target cell, and TRGV9 present on the T cell and binds to the second target on the surface of the target cell. and a step for performing the function of providing an antibody for the purpose of providing an antibody to the patient.
[68] The above steps are repeated n times to serve to obtain a second binding domain that binds to a second target on the surface of the target cell, and TRGV9 present on the T cell and n target molecules are The process according to [67] above, further comprising n steps serving to provide a first binding domain for binding, where n is at least 2.
[69] A method for directing T cells expressing TRGV9 to target cells, the method comprising contacting the multispecific TRGV9 antibody according to any one of [25] to [57] above with the target cells. the second target is on the surface of the target cell, and the contacting directs the T cell to the target cell.
[70] A method of inhibiting the growth or proliferation of a target cell, comprising applying the multispecific TRGV9 antibody according to any one of [25] to [57] above to the surface of the target cell. contacting said target cell in which said target cell is present, said contacting being in the presence of said T cell expressing TRGV9, said contacting inhibiting growth or proliferation of said target cell. How to bring about.
[71] A method for eliminating target cells in a subject, the method comprising applying the multispecific TRGV9 antibody according to any one of [25] to [57] above to the second target on the surface of the target cell. , wherein the contacting is in the presence of the T cell expressing the TRGV9, and the contacting results in elimination of the target cell.
[72] A method for treating a disease in a subject, the method comprising administering to the subject an effective amount of the multispecific TRGV9 antibody according to any one of [25] to [57] above, is caused in whole or in part by said target cell, wherein said second target is present on the surface of said target cell.
[73] The method according to [71] or [72] above, wherein the subject is a human.
[74] The method according to any one of [71] to [73] above, wherein the subject is a subject in need of the method.
[75] The multispecific TRGV9 antibody according to any one of [26] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a cancer cell, or The method according to any one of [69] to 74] above.
[76] (i) The cancer cells are adrenal cancer, anal cancer, appendiceal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, fertile cancer Villi, head and neck cancer, Hodgkin's lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, non-Hodgkin's lymphoma, oral cancer, ovarian cancer, pancreatic cancer , prostate cancer, sinus cancer, skin cancer, soft tissue sarcoma spine cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer cells,
(ii) The second target is angiopoietin, BCMA, CD19, CD20, CD22, CD25 (IL2-R), CD30, CD33, CD37, CD38, CD52, CD56, CD123 (IL-3R), cMET, DLL/Notch , EGFR, EpCAM, FGF, FGF-R, GD2, HER2, mesothelin, nectin-4, PAP, PDGFRα, PSA, PSA3, PSMA, RANKL, SLAMF7, STEAP1, TARP, TROP2, VEGF, or VEGF-R, and/or
(iii) the second target is CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, calcium-dependent chloride channel 2, cyclin-B1, 9D7, EpCAM, EphA3, Her2 /neu, telomerase, mesothelin, SAP-1, survival, BAGE family antigen, CAGE family antigen, GAGE family antigen, MAGE family antigen, SAGE family antigen, XAGE family antigen, NY-ESO-1/LAGE-1, PRAME, SSX -2, Melan-A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2, P. The multispecific TRGV9 antibody or method according to [75] above, which is a polypeptide, MClR, prostate-specific antigen, β-catenin, or BRCA1.
[77] The multispecific TRGV9 antibody or method according to [75] above, wherein the second target is CD123.
[78] The multispecific TRGV9 antibody or method according to [75] above, wherein the second target is CD33.
[79] The multispecific TRGV9 antibody or method according to [75] above, wherein the second target is BCMA.
[80] The multispecific TRGV9 antibody or method according to [75] above, wherein the second target is PSMA.
[81] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a T cell, or The method according to any one of [69] to [74] above.
[82] The second target is CDR3, CD16, CD17, CD18, CD20, CD21, CD23, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32b, CD35, CD37, CD38, CD39, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD52, CD53, CD54, CD55, CD56, CD57 , CD58, CD59, CD60a, CD62L, CD63, CD68, CD69, CD70, CD71, CD73, CD74, CD75S, CD80, CD81, CD82, CD84, CD85A, CD85J, CD86, CD87, CD92, CD94, CD95, CD96, CD97, CD98, CD99 , CD99R, CD100, CD101, CD102, CD103, CD107a, CD107b, CD108, CD109, CD119, CD120a, CD120b, CD121a, CD121b, CD122, CD124, CD126, CD127, CD128, CD129, CD1 30, CD132, CD134, CD137, CD146, CD147, CD148, CD150, CD152, CD153, CD154, CD156b, CD158a, CD158b1, CD158b2, CD158e1/e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD158k, CD159a, C D160, CD161, CD162, CD164, CD172g, CD178, CD181, CD182, CD183, CD184, CD185, CD186, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CDw198, CDw199, CD205, CD210a, CDw210b, CD212, CD215, CD21 7, CD218a, CD218b, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD229, CD230, CD231, CD244, CD245, CD246, CD247, CD253, CD254, CD255, CD256, CD257, CD258, CD259, CD260, CD2 61, CD262, CD263, CD264, CD267, CD268, CD270, CD272, CD273, CD274, CD275, CD277, CD278, CD279, CD283, CD288, CD289, CD290, CD294, CD295, CD296, CD298, CD300a, CD300c, CD300e, CD305, CD306, CD307c, CD314, CD316, The multispecific TRGV9 antibody or method according to [81] above, which is CD317, CD319, CD321, CD328, CD351, CD352, CD352, CD354, CD355, CD357, CD358, CD359, CD360, CD361, CD362, or CD363.
[83] The multispecific TRGV9 antibody or method according to [81] above, wherein the second target is TRBC1.
[84] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a B cell, or The method according to any one of [69] to [74] above.
[85] The second target is CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD6, CD9, CD11a, CD11b, CD11c, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49b, CD49c, C D49d, CD50, CD52, CD53, CD54, CD55, CD58, CD60a, CD62L, CD63, CD68, CD69, CD70, CD72, CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD8 5E, CD85I, CD85J, CD86, CD92, CD95, CD97, CD98, CD99, CD100, CD102, CD108, CD119, CD120a, CD120b, CD121b, CD122, CD124, CD125, CD126, CD130, CD132, CD137, CD138, CD139, CD147, CD148, CD150, CD152, CD162, CD164, CD166, CD167a, CD170, CD171, CD175, CD175s, CD180, CD184, CD185, CD192, CD196, CD197, CD200, CD205, CD201a, CDw210 b, CD212, CD213a1, CD213a2, CD215, CD217 , CD218a, CD218b, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD267-270, CD272, CD274, CD275, CD277, CD279, CD283, CD289, CD290, CD295, CD298, CD300, CD300c, CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD314, CD215, CD316, CD317, The multispecificity according to [84] above, which is CD319, CD321, CD327, CD328, CD329, CD338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD360, CD361, CD362, or CD363 TRGV9 Antibodies or methods.
[86] The multispecific TRGV9 antibody according to [84] above, wherein the second target is BCMA.
[87] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a dendritic cell. Or the method according to any one of [69] to [74] above.
[88] The second target is CD1a, CD1b, CD1c, CD1d, CD1e, CD11b, CD11c, CD16, CD17, CD18, CD19, CD21, CD23, CD29, CD33, CD35, CD36, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD48, CD49d, CD49e, CD58, CD64a, CD68, CD73, CD74, CD80, CD81, CD83, CD84, CD85A, CD85D, CD85E, CD85G, CD8 5J, CD86, CD88, CD97, CD101, CD116, CD120a, CD120b, CD123, CD139, CD148, CD150, CD156b, CD157, CD167, CD168, CD169, CD170, CD171, CD172a, CD172b, CD180, CD184, CD18 5, CD193, CD196, CD197, CD200, CD205, CD206, CD207, CD208, CD209, CDw210b, CD213a1, CD217, CD218a, CD218b, CD220, CD221, CD222, CD227, CD229, CD230, CD232, CD244, CD252, CD256, CD2 57, CD258, CD265, CD270, CD271, CD272, CD273, CD274, CD275, CD276, CD277, CD283, CD286, CD288, CD289, CD290, CD295, CD298, CD300a, CD300c, CD300e, CD301, CD302, CD303, CD304, CD305, CD312, CD317, CD319, CD320, CD328, The multispecific TRGV9 antibody or method according to [87] above, which is CD352, CD354, CD357, or CD361.
[89] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a NK cell, or The method according to any one of [69] to [74] above.
[90] The second target is CD2, CD7, CD8a, CD10, CD11a, CD11b, CD11c, CDw12, CD16, CD18, CD25, CD26, CD27, CD29, CD30, CD31, CD32c, CD38, CD39, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49d, CD49e, CD50, CD52, CD53, CD55, CD56, CD7, CD58, CD59, CD62L, C D63, CD69, CD81, CD82, CD84, CD85C, CD85E, CD85J, CD87, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CD119, CD120a, CD120b, CD122, CD130, CD132, CD147, CD14 8, CD158a, CD158b1, CD158b2, CD158d, CD158e1/e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD158k, CD159a, CD159c, CD160, CD161, CD172g, CD178, CD183, CD185, CDw210b, CD 212, CD217, CD218a, CD218b, CD220, CD221, CD222, CD223, CD225, CD226, CD229, CD230, CD232, CD244, CD247, CD257, CD261, CD262, CD263, CD264, CD270, CD277, CD280, CD295, CD298, CD305, CD314, CD3 16, CD317, CD319, CD321, CD328, The multispecific TRGV9 antibody or method according to [89] above, which is CD329, CD335, CD336, CD337, CD352, CD354, CD355, CD357, CD360, CD361, or CD363.
[91] The multispecific TRGV9 according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a stem cell or a stem cell precursor. antibody, or the method according to any one of [69] to [74] above.
[92] The second target is CD8a, CDw12, CD13, CD15, CD19, CD21, CD22, CD29, CD30, CD33, CD34, CD36, CD38, CD40, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD48, CD49b, CD49d, CD49e, CD49f, CD50, CD53, CD55, CD64a, CD68, CD71, CD72, CD73, CD81, CD82, CD85A, CD85 K, CD90, CD99, CD104, CD105, CD109, CD110, CD111, CD112, CD114, CD115, CD117, CD123, CD124, CD126, CD127, CD130, CD131, CD133, CD135, CD138, CD151, CD157, CD162, CD1 64, CD168, CD172a, CD173, CD174, CD175, CD175s, CD176, CD183, CD191, CD200, CD201, CD205, CD217, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD235a, C D235b, CD236, CD236R, CD238, CD240, The multispecific TRGV9 antibody or method according to [91] above, which is CD242, CD243, CD277, CD292, CDw293, CD295, CD298, CD309, CD318, CD324, CD325, CD338, CD344, CD349, or CD350.
[93] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a monocyte or a macrophage. , or the method according to any one of [69] to [74] above.
[94] The second target is CD1a, CD1b, CD1c, CD4, CD9, CD11a, CD11b, CD11c, CD11d, CDw12, CD13, CD14, CD15, CD16, CD17, CD18, CD23, CD25, CD26, CD29, CD30, CD31, CD32a, CD32b, CD32c, CD33, CD35, CD36, CD37, CD38, CD39, CD40, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, C D49b, CD49c, CD49d, CD49e, CD49f, CD50, CD51, CD52, CD53, CD54, CD55, CD58, CD59, CD60a, CD61, CD63, CD64a, CD65, CD66, CD68, CD69, CD72, CD74, CD75, CD75S, CD80, CD8 1, CD82, CD84, CD85A, CD85C, CD85D, CD85E, CD85F, CD85G, CD85I, CD85J, CD85K, CD86, CD87, CD88, CD89, CD91, CD92, CD93, CD95, CD97, CD98, CD99, CD99R, CD1 00, CD101, CD102, CD105, CD111, CD112, CD114, CD115, CD116, CD119, CD120a, CD120b, CD121b, CD122, CD124, CD127, CD130, CD131, CD132, CD136, CD137, CD139, CD141, CD142, CD143, CD147, CD148, CD153, CD155, CD156a, CD156b, CD156c, CD157, CD162, CD163, CD164, CD165, CD166, CD168, CD169, CD170, CD171, CD172a, CD172b, CD180, CD181, CD182, CD18 4, CD185, CD191, CD192, CD194, CD195, CDw198, CD24, CD205, CD206, CD209, CD210a, CDw210b, CD213a1, CD213a2, CD217, CD220, CD221, CD222, CD224, CD226, CD227, CD230, CD232, CD244, CD 252, CD256, CD257, CD258, CD261, CD262, CD263, CD264, CD265, CD267, CD268, CD270, CD272, CD273, CD274, CD275, CD276, CD277, CD280, CD281, CD282, CD284, CD286, CD288, CD289, CD295, CD2 97, CD298, CD300a, CD300c, CD300e, CD301, CD302, CD305, CD306, CD312, CD214, CD315, CD317, CD319, CD321, CD328, CD329, CD338, CD351, CD352, CD352, CD354, CD357, CD358, CD360, CD3 61, or CD362, the above [93 The multispecific TRGV9 antibody or method described in ].
[95] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a granulocyte, or The method according to any one of [69] to [74] above.
[96] The second target is CD11a, CD11b, CD11c, CDw12, CD13, CD14, CD15, CD16, CD16b, CD17, CD18, CD23, CD24, CD29, CD31, CD32a, CD32b, CD32c, CD33, CD35, CD37, CD43, CD44, CD45, CD45RB, CD45RO, CD46, CD47, CD50, CD53, CD55, CD58, CD59, CD60a, CD62L, CD63, CD64a, CD65, CD65s, CD66a, CD66b, CD66c, CD 66d, CD68, CD69, CD75S, CD82, CD85A, CD85D, CD85K, CD87, CD88, CD89, CD92, CD93, CD95, CD97, CD98, CD100, CD101, CD107a, CD107b, CD114, CD116, CD119, CD120a, CD1 20b, CD123, CD125, CD130, CD131, CD132, CD139, CD141, CD147, CD148, CD153, CD156a, CD156b, CD157, CD162, CD170, CD171, CD172a, CD177, CD178, CD181, CD182, CD183, CD192, CD193, CD195, CD203c, CD217, CD218a, CD218b, CD220, CD221, CD222, CD230, CD232, CD244, CD256, CD257, CD258, CD261, CD262, CD263, CD264, CD268, CD270, CD274, CD275, CD281, CD282, CD 289, CD290, CD294, CD295, CD298, The multispecific TRGV9 antibody or method according to [95] above, which is CD302, CD305, CD312, CD314, CD321, CD328, CD329, CD352, CD354, CD360, or CD362.
[97] The multispecific TRGV9 antibody according to any one of [25] to [57] above, or the above, wherein the second target is present on the surface of a target cell, and the target cell is a platelet. The method according to any one of [69] to [74].
[98] The second target is CD9, CD17, CD18, CD23, CD29, CD31, CD32a, CD32b, CD36, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD46, CD47, CD62P, CD63, CD69, CD82, CD84, CD98, CD99, CD107a, CD107b, CD109, CD110, CD111, CD112, CD114, CD140a, CD141, CD147, CD148, CD151, CD165, CD194, CD226, CD295, CD29 8, or CD321, the above [97 The multispecific TRGV9 antibody or method described in ].
[99] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is a red blood cell, or the multispecific TRGV9 antibody according to any one of [25] to [57] above, or the above-mentioned The method according to any one of [69] to [74].
[100] The second target is CD35, CD36, CD44, CD47, CD49e, CD55, CD58, CD59, CD75S, CD99, CD108, CD111, CD139, CD147, CD173, CD176, CD233, CD234, CD235a, CD2 35b, The multispecific TRGV9 antibody or method according to [99] above, which is CD236, CD236R, CD238, CD239, CD240, CD241, CD242, or CD324.
[101] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is an endothelial cell, or The method according to any one of [69] to [74] above.
[102] The second target is CD9, CD10, CD13, CD17, CD29, CD30, CD31, CD32b, CD34, CD36, CD39, CD40, CD44, CD46, CD47, CD49b, CD49c, CD49d, CD4e, CD49f, CD50, CD51, CD54, CD5, CD58, CD61, CD62E, CD62P, CD63, CD71, CD73, CD74, CD75S, CD77, CD81, CD82, CD86, CD87, CD88, CD90, CD92, CD93, CD98, CD99, C D102, CD104, CD105, CD106, CD107a, CD107b, CD109, CD110, CD111, CD112, CD114, CD117, CD119, CD120a, CD120b, CD121a, CD123, CD130, CD133, CD138, CD14 0a, CD140b, CD141, CD142, CD143, CD144, CDw154, CD146, CD147, CD150, CD151, CD156b, CD157, CD166, CD171, CD173, CD175S, CD176, CD178, CD184, CD192, CD200, CD201, CD202b, CD206, CD209 , CD213a1, CD217, CD218a, CD220, CD221, The above-mentioned [ 101] Multispecific TRGV9 antibodies or methods.
[103] The multispecific TRGV9 antibody according to any one of [25] to [57] above, wherein the second target is present on the surface of a target cell, and the target cell is an epithelial cell, or The method according to any one of [69] to [74] above.
[104] The second target is CD1d, CD9, CD13, CD18, CD21, CD23, CD24, CD26, CD29, CD39, CD40, CD44, CD46, CD47, CD49b, CD49c, CD49e, CD49f, CD52, CD55, CD58, CD66a, CD66c, CD66e, CD66f, CD73, CD74, CD75S, CD77, CD81, CD82, CD88, 91, CD92, CD98, CD99, CD104, CD110, CD111, CD112, CD113, CD114, CD11 8, CD120a, CD120b, CD124, CD129, CD133, CD136, CD137, CD138, CD141, CD142, CD143, CDw145, CD151, CD164, CD165, CD166, CD167a, CD171, CD174, CD175, CD175S, CD176, CD178, CD193, CD206, CD213a2, CD217, CD220, CD221, CD222, CD224, CD227, CD230, CD234, CD239, CD249, CD286, CD295, CD296, CD321, CD324, CD326, CD331, CD332, CD333, CD334, CD339, CD3 40, CD344, or CD350, the above Multispecific TRGV9 antibody or method according to [103].
[105] According to any one of [25] to [57] above, wherein the second target is a pathogen, and optionally the target cell is a cell having a pathogen antigen on the surface of the target cell. The multispecific TRGV9 antibody described above, or the method described in any one of [69] to [74] above.
[106] The multispecific TRGV9 antibody or method according to [105] above, wherein the pathogen is a virus.
[107] The virus belongs to the Adenoviridae, Arenaviridae, Astroviridae, Bunyaviridae, Caliciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Hepeviridae, Orthomyxoviridae. , Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Polyomaviridae, Poxviridae, Reoviridae, Retroviridae, Rhabdoviridae, or Togaviridae; Multispecific TRGV9 antibody or method according to [106].
[108] The virus is adenovirus, coronavirus, Coxsackie virus, Epstein-Barr virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus type 2, cytomegalovirus, human herpes virus type 8, The human immunodeficiency virus, influenza virus, measles virus, mumps virus, human papillomavirus, parainfluenza virus, poliovirus, rabies virus, respiratory syncytial virus, rubella virus, or varicella-zoster virus, as described in [106] above. multispecific TRGV9 antibodies or methods.
[109] The multispecific TRGV9 antibody or method according to [105] above, wherein the pathogen is a bacterium.
[110] The bacteria are Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacteria, Mycoplasma, The multispecific TRGV9 antibody or method according to [109] above, which is a bacterium of the genus Neisseria, Pseudomonas, Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, or Yersinia.
[111] The multispecific TRGV9 antibody or method according to [105] above, wherein the pathogen is a parasite.
[112] The multispecific TRGV9 antibody or method according to [111] above, wherein the parasite is a protozoa, a helminth, or an ectoparasite.
[113] (i) Whether the protozoan is of the genus Entamoeba, Giardia, Leishmania, Balantidium, Plasmodium, or Cryptosporidium;
(ii) the helminth is a fluke, a tapeworm, a hookworm, or a roundworm, or
(iii) The multispecific TRGV9 antibody or method according to [112] above, wherein the ectoparasite is an arthropod.
[114] The pathogen is acute flaccid myelitis (AFM), anaplasmosis, anthrax, babesiosis, botulism, brucellosis, campylobacteriosis, carbapenem-resistant infection, chancroid, chikungunya virus infection, chlamydia, Ciguatera poisoning, Difficile infection, Perfringens, Coccidioidomycosis fungal infection, Coronavirus infection, Covid-19 (SARS-CoV-2), Creutzfeldt-Jakob disease/Transmissible spongiform encephalopathy, Cryptosporidiosis ), cyclosporiasis, dengue fever 1, 2, 3, or 4, diphtheria, Escherichia coli infection/Shiga toxin-producing (STEC), eastern equine encephalitis, hemorrhagic fever (Ebola), ehrlichiosis, arbovirus or parainfectious encephalitis, Non-polio enterovirus, D68 enterovirus (EV-D68), giardiasis, glanders, gonococcal infection, inguinal granuloma, Haemophilus influenzae infection type B (Hib or H-flu), hantavirus pulmonary syndrome (HPS), Hemolytic uremic syndrome (HUS), hepatitis A (Hep A), hepatitis B (Hep B), hepatitis C (Hep C), hepatitis D (Hep D), hepatitis E (Hep E), herpes , herpes zoster, histoplasmosis, human immunodeficiency virus/AIDS (HIV/AIDS), human papillomavirus (HPV), influenza (Flu), Legionnaires' disease, leprosy, leptospirosis, listeria disease (listeria), Lyme disease, lymphogranuloma inguinale (LGV), malaria, measles, melioidosis, meningitis (viral), meningococcal disease (meningitis (bacterial)), Middle East respiratory disease MERS-CoV, mumps, norovirus, lice infestation, pelvic infection (PID), pertussis (pertussis), plague (glandular, septic, pneumonic), pneumococcal disease (pneumonia), polio Viral infections (polio), Powassan, psittacosis, lice, pustular diseases (smallpox, monkeypox, cowpox), Q fever, rabies, rickettsiosis (Rocky Mountain spotted fever), rubella (German measles), salmonella Gastroenteritis (Salmonella), Scabies, Scombroid, Sepsis, Severe Acute Respiratory Syndrome (SARS), Shigella Gastroenteritis (Shigella), Smallpox, Methicillin-Resistant Staphylococcal Infection (MRSA), Staphylococcal Food Poisoning Enterotoxin B Poisoning (Staphylococcal food poisoning), vancomycin intermediate saphylococcal infection (VISA), vancomycin-resistant staphylococcal infection (VRSA), group A streptococcal infection (invasive) (Strep A (invasive), group B streptococcal infection (Strep-B), streptococcal toxic shock syndrome STSS toxic shock, syphilis (first stage, second stage, early latent, late latent, congenital), tetanus infection, trichomoniasis, trichonosis infection, tuberculosis (TB) , latent tuberculosis (LTBI), tularemia, typhoid group D, vaginosis, varicella (varicella), Vibrio cholerae (cholera), vibriosis (vibrio), Ebola virus hemorrhagic fever, Lasa virus hemorrhagic fever, Marburg virus hemorrhagic fever, West The multispecific TRGV9 antibody or method according to [105] above, which causes an infection selected from the group consisting of Nile virus, yellow fever, Yersenia, and Zika virus infections.

Claims

An antibody that binds to T cell receptor gamma variable 9 (TRGV9), comprising:
(1) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 having the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 105;
(2) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 113, and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 114;
(3) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 123, and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 124, or (4) (i) each of the sequences a VH having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of the VH having the amino acid sequence of SEQ ID NO: 133, and (ii) each having the amino acid sequence of SEQ ID NO: 134; An antibody comprising a VL comprising VL CDR1, VL CDR2, and VL CDR3, having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of a VL having.

2. The antibody of claim 1, wherein the antibody is a multispecific antibody.

(a) the antibody is a bispecific antibody;
(b) said antibody is a trispecific antibody, or
(c) The antibody of claim 2 , wherein the antibody is a tetraspecific antibody .

The antibody according to any one of claims 1 to 3 , wherein the second target is present on the surface of a target cell.

5. The antibody of claim 4 , wherein the second target is CD123.

A multispecific TRGV9 antibody, comprising:
(a) a first binding domain that binds to TRGV9, wherein the first binding domain comprises:
(1) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 7, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 8;
(2) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 34, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of a light chain variable region (VL) having the amino acid sequence of SEQ ID NO: 8;
(3) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 35, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 8;
(4) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 36, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 8;
(5) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 65, and (ii) A VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 of VL having the amino acid sequence of SEQ ID NO: 66;
(6) (i) a VH comprising VH CDR1, VH CDR2, and VH CDR3, each having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of VH having the amino acid sequence of SEQ ID NO: 67, and (ii) a VL comprising VL CDR1, VL CDR2, and VL CDR3, each having the amino acid sequence of VL CDR1, VL CDR2, and VL CDR3 having the amino acid sequence of SEQ ID NO: 68, or (7) (i) each of the sequences (ii) a VH having the amino acid sequence of VH CDR1, VH CDR2, and VH CDR3 of the VH having the amino acid sequence of SEQ ID NO: 95, and (ii) each having the amino acid sequence of SEQ ID NO: 96; a VL comprising VL CDR1, VL CDR2, and VL CDR3, having the amino acid sequences of VL CDR1, VL CDR2, and VL CDR3 of a VL having
(b) a second binding domain that binds to a second target that is CD33, TRBC1, BCMA, or PSMA.

A nucleic acid encoding the antibody according to any one of claims 1 to 6 .

A vector comprising the nucleic acid according to claim 7 .

A host cell comprising a vector according to claim 8 .

A pharmaceutical composition comprising the antibody according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

11. A method of manufacturing a pharmaceutical composition according to claim 10 , comprising combining the antibody with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

7. A composition for use in a method of activating T cells expressing TRGV9, the composition comprising the antibody according to any one of claims 1 to 6, contacting said antibody with said antibody .

A process for producing an antibody that binds to two or more target molecules, said process functioning to obtain a first binding domain that binds to TRGV9 present on a T cell; a step for obtaining a second binding domain that binds to a second target on the surface of a cell; and a step for obtaining a second binding domain that binds to a second target on the surface of a cell; A process that includes steps for performing the functions provided.

7. A composition for use in a method of directing T cells expressing TRGV9 to target cells , said composition comprising a multispecific TRGV9 antibody according to any one of claims 1 to 6; The method includes contacting the multispecific TRGV9 antibody with the target cell, wherein the second target is present on the surface of the target cell, and the contacting causes the T cell to contact the target cell. A composition that orients to.

7. A composition for use in a method of inhibiting the growth or proliferation of a target cell, said composition comprising a multispecific TRGV9 antibody according to any one of claims 1 to 6, said method comprising: contacting the multispecific TRGV9 antibody with the target cell in which the second target is present on the surface of the target cell, wherein the contacting is in the presence of the T cell expressing the TRGV9. and wherein said contacting results in inhibition of growth or proliferation of said target cell.

7. A composition for use in a method of eliminating target cells in a subject , said composition comprising the multispecific TRGV9 antibody of any one of claims 1 to 6, said method comprising said multispecific TRGV9 antibody according to any one of claims 1 to 6. contacting a specific TRGV9 antibody with the target cell where the second target is present on the surface of the target cell, the contacting being in the presence of the T cell expressing the TRGV9; The composition , wherein said contacting results in elimination of said target cell.

7. A composition for use in a method of treating a disease in a subject, said composition comprising a multispecific TRGV9 antibody according to any one of claims 1 to 6, said method comprising: administering said multispecific TRGV9 antibody to said subject, wherein said disease is caused in whole or in part by said target cell, wherein said second target is present on the surface of said target cell.

A composition according to any one of claims 14 to 17 , wherein said subject is a subject in need of said method.

The multispecific TRGV9 antibody according to any one of claims 1 to 6 , or the multispecific TRGV9 antibody according to claims 14 to 17 , wherein the second target is on the surface of a target cell, and the target cell is a cancer cell. Composition according to any one of the above.

(i) The cancer cells are adrenal cancer, anal cancer, appendiceal cancer, bile duct cancer, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gallbladder cancer, gestational villus, head and neck cancer. cancer, Hodgkin lymphoma, intestinal cancer, kidney cancer, leukemia, liver cancer, lung cancer, melanoma, mesothelioma, multiple myeloma, neuroendocrine tumors, non-Hodgkin lymphoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer , sinus cancer, skin cancer, soft tissue sarcoma, spinal cancer, stomach cancer, testicular cancer, pharyngeal cancer, thyroid cancer, uterine cancer, endometrial cancer, vaginal cancer, or vulvar cancer cells,
(ii) The second target is angiopoietin, BCMA, CD19, CD20, CD22, CD25 (IL2-R), CD30, CD33, CD37, CD38, CD52, CD56, CD123 (IL-3R), cMET, DLL/Notch , EGFR, EpCAM, FGF, FGF-R, GD2, HER2, mesothelin, nectin-4, PAP, PDGFRα, PSA, PSA3, PSMA, RANKL, SLAMF7, STEAP1, TARP, TROP2, VEGF, or VEGF-R, and/or (iii) the second target is CEA, immature laminin receptor, TAG-72, HPV E6, HPV E7, BING-4, calcium-dependent chloride channel 2, cyclin-B1, 9D7, EpCAM, EphA3, Her2/neu, telomerase, mesothelin, SAP-1, survival, BAGE family antigen, CAGE family antigen, GAGE family antigen, MAGE family antigen, SAGE family antigen, XAGE family antigen, NY-ESO-1/LAGE-1, PRAME, SSX-2, Melan-A, MART-1, Gp100, pmel17, tyrosinase, TRP-1, TRP-2, P. 20. The multispecific TRGV9 antibody or composition of claim 19 , which is a polypeptide, MClR, prostate specific antigen, β-catenin, or BRCA1.

(a) the second target is CDR3, CD16, CD17, CD18, CD20, CD21, CD23, CD25, CD26, CD27, CD28, CD29, CD30, CD31, CD32b, CD35, CD37, CD38, CD39, CD43, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD50, CD52, CD53, CD54, CD55, CD56, CD57 , CD58, CD59, CD60a, CD62L, CD63, CD68, CD69, CD70, CD71, CD73, CD74, CD75S, CD80, CD81, CD82, CD84, CD85A, CD85J, CD86, CD87, CD92, CD94, CD95, CD96, CD97, CD98, CD99 , CD99R, CD100, CD101, CD102, CD103, CD107a, CD107b, CD108, CD109, CD119, CD120a, CD120b, CD121a, CD121b, CD122, CD124, CD126, CD127, CD128, CD129, CD1 30, CD132, CD134, CD137, CD146, CD147, CD148, CD150, CD152, CD153, CD154, CD156b, CD158a, CD158b1, CD158b2, CD158e1/e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD158k, CD159a, C D160, CD161, CD162, CD164, CD172g, CD178, CD181, CD182, CD183, CD184, CD185, CD186, CD191, CD192, CD193, CD194, CD195, CD196, CD197, CDw198, CDw199, CD205, CD210a, CDw210b, CD212, CD215, CD21 7, CD218a, CD218b, CD220, CD221, CD222, CD223, CD224, CD225, CD226, CD227, CD229, CD230, CD231, CD244, CD245, CD246, CD247, CD253, CD254, CD255, CD256, CD257, CD258, CD259, CD260, CD2 61, CD262, CD263, CD264, CD267, CD268, CD270, CD272, CD273, CD274, CD275, CD277, CD278, CD279, CD283, CD288, CD289, CD290, CD294, CD295, CD296, CD298, CD300a, CD300c, CD300e, CD305, CD306, CD307c, CD314, CD316, is CD317, CD319, CD321, CD328, CD351, CD352, CD352, CD354, CD355, CD357, CD358, CD359, CD360, CD361, CD362, or CD363, or
(b) The multispecific TRGV9 antibody or composition of claim 20 , wherein the second target is TRBC1 .

(a) the second target is CD1a, CD1b, CD1c, CD1d, CD2, CD5, CD6, CD9, CD11a, CD11b, CD11c, CD17, CD18, CD19, CD20, CD21, CD22, CD23, CD24, CD25, CD26, CD27, CD29, CD30, CD31, CD32a, CD32b, CD35, CD37, CD38, CD39, CD40, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49b, CD49c, C D49d, CD50, CD52, CD53, CD54, CD55, CD58, CD60a, CD62L, CD63, CD68, CD69, CD70, CD72, CD73, CD74, CD75, CD75S, CD77, CD79a, CD79b, CD80, CD81, CD82, CD83, CD84, CD8 5E, CD85I, CD85J, CD86, CD92, CD95, CD97, CD98, CD99, CD100, CD102, CD108, CD119, CD120a, CD120b, CD121b, CD122, CD124, CD125, CD126, CD130, CD132, CD137, CD138, CD139, CD147, CD148, CD150, CD152, CD162, CD164, CD166, CD167a, CD170, CD171, CD175, CD175s, CD180, CD184, CD185, CD192, CD196, CD197, CD200, CD205, CD201a, CDw210 b, CD212, CD213a1, CD213a2, CD215, CD217 , CD218a, CD218b, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD229, CD230, CD232, CD252, CD252, CD254, CD255, CD256, CD257 CD258, CD259, CD260, CD261, CD262, CD263, CD264, CD267-270, CD272, CD274, CD275, CD277, CD279, CD283, CD289, CD290, CD295, CD298, CD300, CD300c, CD305, CD306, CD307a, CD307b, CD307c, CD307d, CD307e, CD314, CD215, CD316, CD317, is CD319, CD321, CD327, CD328, CD329, CD338, CD351, CD352, CD353, CD354, CD355, CD356, CD357, CD358, CD360, CD361, CD362, or CD363, or
(b) The multispecific TRGV9 antibody or composition of claim 20 , wherein the second target is BCMA .

The second target is CD1a, CD1b, CD1c, CD1d, CD1e, CD11b, CD11c, CD16, CD17, CD18, CD19, CD21, CD23, CD29, CD33, CD35, CD36, CD38, CD39, CD40, CD45, CD45RA , CD45RB, CD45RC, CD45RO, CD48, CD49d, CD49e, CD58, CD64a, CD68, CD73, CD74, CD80, CD81, CD83, CD84, CD85A, CD85D, CD85E, CD85G, CD85J, CD86, CD8 8, CD97, CD101, CD116 , CD120a, CD120b, CD123, CD139, CD148, CD150, CD156b, CD157, CD167, CD168, CD169, CD170, CD171, CD172a, CD172b, CD180, CD184, CD185, CD193, CD1 96, CD197, CD200, CD205, CD206, CD207 , CD208, CD209, CDw210b, CD213a1, CD217, CD218a, CD218b, CD220, CD221, CD222, CD227, CD229, CD230, CD232, CD244, CD252, CD256, CD257, CD258, CD 265, CD270, CD271, CD272, CD273, CD274 , CD275, CD276, CD277, CD283, CD286, CD288, CD289, CD290, CD295, CD298, CD300a, CD300c, CD300e, CD301, CD302, CD303, CD304, CD305, CD312, CD317 , CD319, CD320, CD328, CD352, CD354 21. The multispecific TRGV9 antibody or composition of claim 20 , which is CD357, or CD361.

The second target is CD2, CD7, CD8a, CD10, CD11a, CD11b, CD11c, CDw12, CD16, CD18, CD25, CD26, CD27, CD29, CD30, CD31, CD32c, CD38, CD39, CD43, CD44, CD45 , CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49d, CD49e, CD50, CD52, CD53, CD55, CD56, CD7, CD58, CD59, CD62L, CD63, CD69, CD81, CD82, CD84 , CD85C, CD85E, CD85J, CD87, CD94, CD95, CD96, CD97, CD98, CD99, CD99R, CD100, CD119, CD120a, CD120b, CD122, CD130, CD132, CD147, CD148, CD158a, CD158b1, CD158b2, CD158d, CD158e1 /e2, CD158f, CD158g, CD158h, CD158i, CD158j, CD158k, CD159a, CD159c, CD160, CD161, CD172g, CD178, CD183, CD185, CDw210b, CD212, CD217, CD21 8a, CD218b, CD220, CD221, CD222, CD223, CD225 , CD226, CD229, CD230, CD232, CD244, CD247, CD257, CD261, CD262, CD263, CD264, CD270, CD277, CD280, CD295, CD298, CD305, CD314, CD316, CD317, CD 319, CD321, CD328, CD329, CD335 21. The multispecific TRGV9 antibody or composition of claim 20 , which is CD336, CD337, CD352, CD354, CD355, CD357, CD360, CD361, or CD363.

The second target is CD8a, CDW12, CD15, CD15, CD19, CD21, CD29, CD29, CD29, CD30, CD33, CD33, CD36, CD36, CD36, CD40, CD41, CD42A, CD42C, CD42C, CD42C, CD42C 42D, CD43, CD45, CD45RA , CD45RB, CD45RC, CD45RO, CD48, CD49b, CD49d, CD49e, CD49f, CD50, CD53, CD55, CD64a, CD68, CD71, CD72, CD73, CD81, CD82, CD85A, CD85K, CD90, CD99 , CD104, CD105, CD109 , CD110, CD111, CD112, CD114, CD115, CD117, CD123, CD124, CD126, CD127, CD130, CD131, CD133, CD135, CD138, CD151, CD157, CD162, CD164, CD168, CD 172a, CD173, CD174, CD175, CD175s , CD176, CD183, CD191, CD200, CD201, CD205, CD217, CD220, CD221, CD222, CD224, CD225, CD226, CD227, CD228, CD229, CD230, CD235a, CD235b, CD236, CD236R, CD238, CD240, CD242, CD243 , CD277, CD292, CDw293, CD295, CD298, CD309 , CD318, CD324, CD325, CD338, CD344, CD349, or CD350 .

The second target is CD1a, CD1b, CD1c, CD4, CD9, CD11a, CD11b, CD11c, CD11d, CDw12, CD13, CD14, CD15, CD16, CD17, CD18, CD23, CD25, CD26, CD29, CD30, CD31 , CD32a, CD32b, CD32c, CD33, CD35, CD36, CD37, CD38, CD39, CD40, CD44, CD45, CD45RA, CD45RB, CD45RC, CD45RO, CD46, CD47, CD48, CD49a, CD49b, CD49 c, CD49d, CD49e, CD49f , CD50, CD51, CD52, CD53, CD54, CD55, CD58, CD59, CD60a, CD61, CD63, CD64a, CD65, CD66, CD68, CD69, CD72, CD74, CD75, CD75S, CD80, CD81, CD82, CD84 , CD85A , CD85C, CD85D, CD85E, CD85F, CD85G, CD85I, CD85J, CD85K, CD86, CD87, CD88, CD89, CD91, CD92, CD93, CD95, CD97, CD98, CD99, CD99R, CD100, CD101, C D102, CD105, CD111 , CD112, CD114, CD115, CD116, CD119, CD120a, CD120b, CD121b, CD122, CD124, CD127, CD130, CD131, CD132, CD136, CD137, CD139, CD141, CD142, CD143 , CD147, CD148, CD153, CD155, CD156a , CD156b, CD156c, CD157, CD162, CD163, CD164, CD165, CD166, CD168, CD169, CD170, CD171, CD172a, CD172b, CD180, CD181, CD182, CD184, CD185, CD19 1, CD192, CD194, CD195, CDw198, CD24 , CD205, CD206, CD209, CD210a, CDw210b, CD213a1, CD213a2, CD217, CD220, CD221, CD222, CD224, CD226, CD227, CD230, CD232, CD244, CD252, CD256, C D257, CD258, CD261, CD262, CD263, CD264 , CD265, CD267, CD268, CD270, CD272, CD273, CD274, CD275, CD276, CD277, CD280, CD281, CD282, CD284, CD286, CD288, CD289, CD295, CD297, CD298, CD 300a, CD300c, CD300e, CD301, CD302 , CD305, CD306, CD312, CD214, CD315, CD317, CD319, CD321, CD328, CD329, CD338, CD351, CD352, CD352, CD354, CD357, CD358, CD360, CD361, or CD362. , according to claim 20 . Multispecific TRGV9 antibodies or compositions .

The second target is CD11a, CD11b, CD11c, CDw12, CD13, CD14, CD15, CD16, CD16b, CD17, CD18, CD23, CD24, CD29, CD31, CD32a, CD32b, CD32c, CD33, CD35, CD37, CD4 3 , CD44, CD45, CD45RB, CD45RO, CD46, CD47, CD50, CD53, CD55, CD58, CD59, CD60a, CD62L, CD63, CD64a, CD65, CD65s, CD66a, CD66b, CD66c, CD66d, CD68, CD69, CD75S, CD82 , CD85A, CD85D, CD85K, CD87, CD88, CD89, CD92, CD93, CD95, CD97, CD98, CD100, CD101, CD107a, CD107b, CD114, CD116, CD119, CD120a, CD120b, CD123, CD125, CD130, CD131, CD132 , CD139, CD141, CD147, CD148, CD153, CD156a, CD156b, CD157, CD162, CD170, CD171, CD172a, CD177, CD178, CD181, CD182, CD183, CD192, CD193, CD195 , CD203c, CD217, CD218a, CD218b, CD220 , CD221, CD222, CD230, CD232, CD244, CD256, CD257, CD258, CD261, CD262, CD263, CD264, CD268, CD270, CD274, CD275, CD281, CD282, CD289, CD290, CD 294, CD295, CD298, CD302, CD305 21. The multispecific TRGV9 antibody or composition of claim 20 , which is CD312, CD314, CD321, CD328, CD329, CD352, CD354, CD360, or CD362.

The second target is CD9, CD17, CD18, CD23, CD29, CD31, CD32a, CD32b, CD36, CD41, CD42a, CD42b, CD42c, CD42d, CD43, CD46, CD47, CD62P, CD63, CD69, CD82, CD84 , CD98, CD99, CD107a, CD107b, CD109, CD110, CD111, CD112, CD114, CD140a, CD141, CD147, CD148, CD151, CD165, CD194, CD226, CD295, CD298, or CD321 According to claim 20 , Multispecific TRGV9 antibodies or compositions .

The second target is CD35, CD36, CD44, CD47, CD49e, CD55, CD58, CD59, CD75S, CD99, CD108, CD111, CD139, CD147, CD173, CD176, CD233, CD234, CD235a, CD235b, CD 236, CD236R 21. The multispecific TRGV9 antibody or composition of claim 20 , which is CD238, CD239, CD240, CD241, CD242, or CD324.

The second target is CD9, CD10, CD13, CD17, CD29, CD30, CD31, CD32b, CD34, CD36, CD39, CD40, CD44, CD46, CD47, CD49b, CD49c, CD49d, CD4e, CD49f, CD50, CD51 , CD54, CD5, CD58, CD61, CD62E, CD62P, CD63, CD71, CD73, CD74, CD75S, CD77, CD81, CD82, CD86, CD87, CD88, CD90, CD92, CD93, CD98, CD99, CD102, CD10 4, CD105 , CD106, CD107a, CD107b, CD109, CD110, CD111, CD112, CD114, CD117, CD119, CD120a, CD120b, CD121a, CD123, CD130, CD133, CD138, CD140a, CD140b, C D141, CD142, CD143, CD144, CDw154, CD146 , CD147, CD150, CD151, CD156b, CD157, CD166, CD171, CD173, CD175S, CD176, CD178, CD184, CD192, CD200, CD201, CD202b, CD206, CD209, CD213a1, CD2 17, CD218a, CD220, CD221, CD222, CD224 , CD225, CD228, CD230, CD234, CD239, CD242, CD246, CD248, CD252, CD266, CD280, 295, CD297, CD299, CD309, CD321, CD322 , or CD344. GV9 Antibody or composition .

The second target is CD1d, CD9, CD13, CD18, CD21, CD23, CD24, CD26, CD29, CD39, CD40, CD44, CD46, CD47, CD49b, CD49c, CD49e, CD49f, CD52, CD55, CD58, CD66a , CD66c, CD66e, CD66f, CD73, CD74, CD75S, CD77, CD81, CD82, CD88, 91, CD92, CD98, CD99, CD104, CD110, CD111, CD112, CD113, CD114, CD118, CD120a, C D120b, CD124, CD129 , CD133, CD136, CD137, CD138, CD141, CD142, CD143, CDw145, CD151, CD164, CD165, CD166, CD167a, CD171, CD174, CD175, CD175S, CD176, CD178, CD193 , CD206, CD213a2, CD217, CD220, CD221 , CD222, CD224, CD227, CD230, CD234, CD239, CD249, CD286, CD295, CD296, CD321, CD324, CD326, CD331, CD332, CD333, CD334, CD339, CD340, CD344, or C According to claim 20 , which is D350. Multispecific TRGV9 antibodies or compositions as described.

21. The multispecific method of claim 20 , wherein the second target is a pathogen that is a virus, a bacterium, or a parasite , and optionally the target cell is a cell that has a pathogen antigen on the surface of the target cell. TRGV9 antibody or composition .

(a) The virus is Adenoviridae, Arenaviridae, Astroviridae, Bunyaviridae, Caliciviridae, Coronaviridae, Filoviridae, Flaviviridae, Hepadnaviridae, Hepeviridae, Orthomyxoviridae. , is a virus of the Papillomaviridae, Paramyxoviridae, Parvoviridae, Picornaviridae, Polyomaviridae, Poxviridae, Reoviridae, Retroviridae, Rhabdoviridae, or Togaviridae family, or
(b) The virus is adenovirus, coronavirus, Coxsackie virus, Epstein-Barr virus, hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus type 2, cytomegalovirus, human herpes virus type 8, 33. The human immunodeficiency virus, influenza virus, measles virus, mumps virus, human papillomavirus, parainfluenza virus, poliovirus, rabies virus, respiratory syncytial virus, rubella virus, or varicella zoster virus, according to claim 32 . Multispecific TRGV9 antibodies or compositions .

The bacteria include Bacillus, Bartonella, Bordetella, Borrelia, Brucella, Campylobacter, Chlamydia, Chlamydophila, Clostridium, Corynebacterium, Enterococcus, Escherichia, Francisella, Haemophilus, Helicobacter, Legionella, Leptospira, Listeria, Mycobacteria, Mycoplasma, Neisseria, Pseudomonas. 33. The multispecific TRGV9 antibody or composition of claim 32 , which is a bacterium of the genus Rickettsia, Salmonella, Shigella, Staphylococcus, Streptococcus, Treponema, Ureaplasma, Vibrio, or Yersinia.

33. The multispecific TRGV9 antibody or composition of claim 32 , wherein the parasite is a protozoa, a helminth, or an ectoparasite.